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ABSTRACT
Much has been learned about Mycobacterium tuberculosis, the causative agent
of tuberculosis, “the great white plague,” since the bacterium was isolated and
initially characterized by Robert Koch over a century ago. Over the last decade,
new genetic tools for manipulation of the bacterium have been developed, its
genome has been sequenced, and the search for new vaccines and drug targets
has greatly intensified. Yet, surprisingly little is known about which mycobacterial
genes are truly important for the organism’s ability to persist in the tissues of its
human hosts. The metabolic pathways used by the tubercle bacillus to establish
and maintain a life-long infection have largely been ignored by researchers, yet
they may represent promising new areas for therapeutic intervention. Recently,
one enzyme of the glyoxylate shunt of M. tuberculosis, isocitrate lyase (ICL), was
shown to be required for virulence in experimental infections of mice. The other
enzyme of the glyoxylate shunt, malate synthase (MLS), may also be important
for the intracellular survival of the tubercle bacillus; yet, no studies have been
done to determine its in vivo role. We present here results of genetic studies of
MLS in the saprophyte Mycobacterium smegmatis, and show that MLS, unlike
ICL, is dispensable for growth on acetate or fatty acids. We also describe the dglycerate pathway in M. smegmatis, which enables malate synthase-deficient
bacteria to utilize acetate and fatty acids as sole carbon sources, and which
allows M. smegmatis to grow on glyoxylate. The d-glycerate pathway, however,
does not appear to exist in the pathogenic Mycobacterium tuberculosis.
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CHAPTER 1
Tuberculosis: The Disease and The Bacillus
1.1. The duration of the mycobacterial infection
A white woman had active pulmonary tuberculosis of 41 years’ duration. She had
bilateral bronchiectasis, cavitation in the right upper lobe, a collapsed left lung,
pleural effusion, and an induced left pneumothorax of 36 years’ duration. She
had received no antituberculosis drugs for 28 years from the onset of her illness,
and these drugs, when finally prescribed, were taken inadequately. Pleural
effusion present for 28 years required aspiration…. The patient survived 41 years
with advanced, active, pulmonary tuberculosis with cavitation, a functionless left
lung, and pleural effusion, and she harbored a strain of M. tuberculosis resistant
to all antituberculous drugs except streptomycin. [Edwards et al. 1970]

The report by Edwards and colleagues is noteworthy for several reasons. On the
one hand, it highlights the resilience of the human body in the face of severe
pathological destruction, as the patient survived for decades with one functional
lung. On the other, however, it underlines the tenacity and recalcitrance of the
tubercle bacillus. Despite the best surgical interventions of the time, the care by
numerous physicians in six large military hospitals, and the administration of
antibiotics, the patient was never cured; instead, the bacillus acquired resistance
to all but one of the antibiotics and, by maintaining an active infection, it was
undoubtedly transmitted to other individuals.
Other details of the story make it even more interesting. The patient did
survive for over four decades, but she was the exception rather than the rule, as
studies of patients with such advance disease and cavitation revealed that 85 per
cent died within a year (Barnes and Barnes, 1928). Furthermore, her husband of
30 years was with her at all times, served as her “personal doctor”, and
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administered pneumothorax fills at home, yet he never showed any evidence of
the disease. It is clear, however, that the patient would have shed an enormous
number of multi-drug resistant bacilli in her community, and while her husband
never had an active infection, others may have contracted the disease from her.
This ability of the mycobacteria to persist in the face of the combined
assault of the immune system and antibiotics is a hallmark of tuberculosis. It is
estimated that 90% of infected individuals will not develop clinical disease; of the
10% who do develop disease, some of them will succumb within the first few
years after infection, while the rest will control the infection initially, but develop
tuberculosis later in life (Comstock, 1982). The persistence of the bacterium in
the tissues of otherwise healthy humans has been well documented. HernandezPando and colleagues (2000) used PCR to examine macroscopically normal lung
tissue from individuals who had died from causes other than tuberculosis. In five
of 13 people from Ethiopia and ten of 34 individuals from Mexico, DNA from M.

tuberculosis was detected. The lungs of these humans presumably harbored a
handful of live mycobacteria, which could eventually establish an active infection.
A remarkable example of a reactivation of latent infection was reported in
Denmark, where scientists obtained evidence of endogenous reactivation of M.

tuberculosis after 33 years of latency (Lillebaek et al., 2002). The patient had
presumably received the BCG vaccine prior to infection, did not show signs of
disease after contracting the bacterium, yet presented with active tuberculosis 33
years later.
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1.2. The global burden of the disease
The World Health Organization’s website (www.who.int) provides statistics
regarding the magnitude of the TB epidemic worldwide. Of the 2 billion people
who are currently infected with the tubercle bacillus, 200 million are expected to
develop active tuberculosis. 8.8 million new cases of TB occurred in 2003, with
the overwhelming majority of cases concentrated in 22 countries. About half a
million of these new cases were multi-drug resistant (MDR), with the highest
rates in the former Soviet Union and China, where one in eight patients fails to
respond to standard drug therapy. MDR-TB, however, has been detected in
virtually all of the 109 countries surveyed by the WHO. TB has reached pandemic
status in Africa, which accounts for a quarter of all TB cases, and in Southeast
Asia, in which 6 countries (Bangladesh, China, India, Indonesia, Pakistan and
Philippines) register half of all new cases (WHO, 2005).
TB, malaria and HIV/AIDS kill 6 million people each year, a third of whom
die from TB. TB is the leading killer of HIV-infected individuals; a quarter of a
million TB deaths, most of them in Africa, are associated with HIV/AIDS. The TB
epidemic in the developing world mainly impacts on young adults, who are the
economic drivers of society; in fact, TB is a leading cause of mortality among
young women, especially in Africa. Due to the high rates of TB infection in Africa,
the global incidence of the disease is growing at 1% per year. Areas of high HIV
prevalence in Africa experience more than twice the rate of TB cases (400 per
100,000 people per year) compared to low HIV prevalence areas (WHO, 2005).

3

1.3. The physical nature of the bacillus

M. tuberculosis, and the related fast-growing saprophyte M. smegmatis, belong
to the genus Mycobacterium. This genus comprises a number of species of acidfast, rod-shaped bacteria, and is the only genus in the family Mycobacteriaceae
within the order Actinomycetales. Like other related Actinomycetales, such as

Nocardia and Corynebacterium, mycobacteria have high genomic DNA GC
content and produce mycolic acids as major components of their cell wall. The
tubercle bacilli measure between 1 and 4 µm in length and are 0.3 to 0.6 µm in
diameter; they possess only a single cytoplasmic membrane, but they also have
thick, waxy cell walls. Mycobacteria are obligate aerobes, despite possessing
enzymes required for anaerobic fermentative growth (Cole et al., 1998);
however, they can grow at low O2 concentrations and can even survive long
periods of complete oxygen deprivation (Wayne and Hayes, 1996).
Unlike M. leprae, M. tuberculosis and M. smegmatis can be cultured in
liquid or on solid media containing carbon and nitrogen sources as well as basic
salts and trace elements (Wayne, 1994). M. smegmatis is more amenable to
growth in minimal media than its pathogenic cousin, which makes it a useful
model for metabolic studies. It also doubles every 3-4 hours in culture, and
forms colonies in 3 to 4 days, while M. tuberculosis doubles every 20-24 hours
and forms a colony on agar in 3-4 weeks. All of the experiments described in this
thesis were carried out with M. smegmatis, largely because they were not
feasible, or easily executable, with pathogenic M. tuberculosis.
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The study of mycobacteria has been facilitated by the sequencing of
several mycobacterial genomes over the last decade. They are high-GC (~ 65%)
and lack pathogenicity islands typical of many bacterial pathogens. The genomes
of the virulent laboratory strain H37Rv (Cole et al. 1998), the clinical isolate
CDC1551 (Fleischmann et al., 2002), the animal pathogen M. bovis (Garnier et

al. 2003), as well as the M. leprae genome (Cole et al., 2001), were all recently
decoded. The Institute of Genomic Research (TIGR) has also sequenced and
annotated the genomes of M. aviam paratuberculosis and M. smegmatis mc2155.
A perusal of the genome statistics reveals that M. smegmatis has duplicated a
significant portion of its genetic material. However, this duplication does not
include the glyoxylate shunt glcB gene (which encodes malate synthase) and the
two isocitrate lyase genes (icl1 and icl2).
Mycobacterial species have greatly duplicated the genes involved in fatty
acid biosynthesis, which is perhaps not surprising given that mycobacteria
possess an extremely complex lipid-rich cell wall (Brennan, 2003). Close to ten
percent of the DNA of pathogenic mycobacteria is predicted to be involved in
lipid metabolism. The M. smegmatis genome displays an equally extensive
expansion. Focusing on the fatty acid degradation (fad) genes, The Institute for
Genomic Research’s (TIGR’s) annotation suggests that there could be as many
as 7 fadA, 9 fadB, around 40 fadD, and more than 40 FadE genes. Comparable
duplication of the fatty acid biosynthesis (fab) genes exists in M. smegmatis.
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1.4. General metabolic features of mycobacteria
The extensive duplication of lipid assimilation and biosynthesis genes appear be
the most striking feature of mycobacterial metabolism. When grown in synthetic
media, mycobacteria behave like most other bacterial species, and can use a
range of substrates as carbon and energy sources (Wheeler and Ratledge,
1994). Mycobacteria possess all the enzymes for glycolysis, the pentose
phosphate pathway, and the tricarboxylic acid and glyoxylate cycles, plus a
number of oxygenases, oxidoreductases, and dehydrogenases. Mycobacteria can
also utilize several anaerobic electron transport chains, such as the nitrate,
fumarate, and possibly nitrite reductases (Cole et al., 1998).
Little is known about the primary carbon sources utilized by mycobacteria

in vivo, but it is thought that lipids might be more readily available for
assimilation than carbohydrates (Wheeler and Ratledge, 1994). Mycobacteria
may in fact use both lipids and carbohydrates in host tissues, and biosynthetic
and degradative reactions could take place simultaneously. Studies by Segal and
Bloch (1956) of virulent bacilli isolated from host tissues suggested that fatty
acids might serve as the major source of carbon and energy in vivo. Recent
studies in our laboratory (McKinney et al., 2000; Muñoz-Elías and McKinney,
2005; Muñoz-Elías et al., 2006) suggest that the ability to degrade and assimilate
lipids for both energy and biosynthetic purposes is of crucial importance to the
tubercle bacillus during the establishment of a persisten infection. A more
complete overview of mycobacterial metabolism will be provided later.
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1.5. Mycobacterial features examined in this thesis
Mycobacterial metabolism, molecular genetics, pathophysiology and persistence,
the immune response of the infected host, and the interaction between the
bacillus and its host at the cellular level have been reviewed extensively
(Wheeler and Ratledge, 1994; Dannerberg and Rook, 1994; McKinney et al.
1998; Wayne and Sohaskey, 2001; Russell, 2001; Clark-Curtiss and Haydell,
2003; Boshoff and Barry, 2005; Muñoz-Elías and McKinney, 2006). This thesis
will focus on the central metabolism of M. tuberculosis and its saprophytic cousin

M. smegmatis. Chapter 2 describes our current understanding of the metabolism
of bacteria grown in vitro, the main organisms studied being Escherichia coli and
some relatives of the Mycobacteriaseae family, such as Corynebacterium and

Streptomyces; the role of the glyoxylate shunt enzymes for growth in vitro and
for the establishment of persistent infection in vivo will be emphasized. Chapter 3
describes the results of studies on the role of the gyoxylate shunt enzyme malate
synthase in the utilization of carbohydrates and fatty acids as carbon sources,
and the role of this pathway in mycobacterial anaplerosis during growth on twocarbon molecules (acetate and glyoxylate) and compounds catabolized to acetylCoA, such as fatty acids. The experiments were done in M. smegmatis, but the
results have important implications for understanding the metabolism of M.

tuberculosis.

7

CHAPTER 2
Bacterial Metabolism In Vitro
2.1. General aspects of in vitro metabolism
Our knowledge of the in vitro metabolism of eubacteria has largely been derived
from studies of enteric organisms, particularly Escherichia coli. The ease of
biochemical and genetic manipulation of E. coli has enabled scientists to assign
unambiguous functions to many of the genes involved in central metabolism.
Thus, in many cases the function of a newly sequenced gene can be adduced
from its homology to functionally chyaracterized E. coli genes. This chapter will
focus on aspects of E. coli metabolism and will summarize our current knowledge
of mycobacterial metabolic pathways, highlighting important differences.
Many species of eubacteria will grow readily on solid or in liquid media
containing basal salts and essential elements in trace amounts, as long as carbon
and nitrogen sources are provided. As mentioned above, most mycobacteria can
be cultured in vitro in synthetic media, M. leprae being a notable exception.
Some organisms with mutations in biosynthetic pathways may require media
supplementation with compounds like thiamine or lipoic acid, vitamins or amino
acids, or precursors for the biosynthesis of coenzymes such as NAD+ and NADH+,
or flavin-containing molecules such as FMN and FAD. Both the pathogenic
tubercle bacillus and its non-pathogenic relative M. smegmatis grow without
requiring such supplements, as can be expected given the completeness of their
genomes for genes involved in the biosynthesis of essential precursors.
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2.2. Carbohydrate metabolism
The most common type of sugar used to culture eubacteria is glucose, a sixcarbon substrate. Glucose can be oxidized to pyruvate via the Embden-Meyerhof
pathway (EMP, a.k.a. glycolysis) or the Entner-Doudoroff pathway (EDP), or it
can be converted to pentose sugars via the pentose phosphate pathway (PPP)
(Fraenkel, 1996). Acetyl-CoA generated from pyruvate is further oxidized to
carbon dioxide and water via the tricarboxylic acid (TCA) cycle. Pentose sugars
are precursors for nucleotides and nucleic acids. The EMP, EDP, and PPP
pathways of eubacteria and eukaryotes are depicted in Figure 2.1.
The first step of glycolysis is the activation of glucose to glucose 6phosphate, which can be done by glucokinase (glk). Enterics use the
phosphoenolpyruvate (PEP) phosphotransferase system (PTS) as the main route
of glucose activation and transport into the cell. M. tuberculosis lacks PTS and
glucokinase homologs, and most likely uses polyphosphate glucokinase (PPGK)
for glucose activation. Glucose-6-phosphate is converted to fructose-6-phosphate
by phosphoglucose isomerase (pgi); E. coli pgi mutants can grow on glucose by
using the PPP (Fraenkel and Horecker, 1965). The conversion of fructose-6phosphate to fructose-1,6-bisphosphate is catalyzed by phosphofructokinase
(pfk); two copies of the enzyme are present in E. coli and in M. tuberculosis,
where functional redundancy seems to exist (Sassetti et al., 2003). The hexose
fructose-1-6-bisphosphate is finally split into the trioses glyceraldehyde-3phosphate and dihydroxyacetone-phosphate, by fructose-1,6-bisphosphate
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Figure 2.1. Routes of glucose degradation. Embden-Meyerhof pathway (EMP) [E. coli
genes shown]: glk, glucose kinase; pgi, phosphoglucose isomerase; pfk,
phosphofructokinase; fba, fructose-1,6-bisphosphate aldolase; tpi, triosephosphate
isomerase; gap, glyceraldehyde 3-phosphate dehydrogenase; pgk, phosphoglycerate
kinase; pgm, phosphoglycerate mutase; eno, enolase; pyk, pyruvate kinase. Glucose-6-

phosphate can be converted to gluconate or 6-phosphogluconate, which can enter the
pentose phosphate pathway (PPP) or the Entner-Doudoroff pathway (EDP). gcd, glucose
dehydrogenase; gntK, gluconate kinase; zwf, glucose 6-phosphate dehydrogenase; pgl,
6-phospho-gluconolactonase; edd, 6-phosphogluconate dehydrogenase; eda, 2-keto-3deoxy-6-phosphogluconate aldolase; gnd, 6-phosphogluconate dehydrogenase; rpe,
ribulose-5-phosphate epimerase; tkt, transketoase; tal, translaldolase. Ribose-5phosphate and rpi, ribose-5-phosphate isomerase not shown. Abbreviations: KGDP, 2keto-3-deoxy-phosphogluconate; GA, glyceraldehyde; GAP, glyceradehyde-3-phosphate;
PGP, glycerate-1,3-bisphosphate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate;
PEP, phosphoenolpyruvate. Modified from Verhees et al. (2003) and Fraenkel (1996).
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aldolase (fba). Triosephosphate isomerase (tpi) interconverts the two threecarbon

compounds.

In

the

lower

branch

of

the

glycolytic

pathway,

glyceraldehyde-3-phosphate is ultimately oxidized to one molecule of pyruvate,
with the concomitant generation of two ATP molecules, by the enzymes
glyceraldehyde-3-phosphate dehydrogenase (gap), phosphoglycerate kinase
(pgk), phosphoglycerate mutase (pgm), enolase (eno), and pyruvate kinase
(pyk).
The pentose phosphate pathway (PPP) can also generate glyceraldehyde3-phosphate, and consists of two branches for production of ribose-5-phosphate,
a precursor for the synthesis of nucleotides and nucleic acids. The first is the
“oxidative branch” which reduces two molecules of NADP+. The second forms
pentoses from hexose and triose phosphates via non-oxidative reactions, which
are catalyzed by transketolase and transaldolase (Horecker, 2002). The study of
the PPP began with the discovery of NADP by Otto Warburg as the coenzyme
required for the oxidation of glucose-6-phosphate to 6-phosphogluconate. Since
the role of NAD+ in glycolysis was well established at the time, an alternative
pathway for oxidation of phospho-hexoses was sought and their conversion to
phosphopentoses was discovered. The PPP fulfills two important functions: it
generates ribose-5-phosphate for biosynthesis of nucelotides, and it provides
reducing power in the form of NADPH. Ribose-5-phosphate can also be formed
from the hexose fructose-6-phosphate and the triose glyceraldehyde-3phosphate by non-oxidative rearrangements catalyzed by transketalose-
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ATP
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NADP NADPH
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Glyceraldehyde-3-P
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Figure 2.2. The pentose phosphate pathway (PPP). Genes: gcd, glucose
dehydrogenase; gntK, gluconate kinase; gnd, 6-phosphogluconate dehydrogenase; zwf,
glucose 6-phosphate dehydrogenase; pgl, 6-phosphogluconolactonase; rpe, ribulose 5phosphate epimerase; rpi, ribose 5-phosphate isomerase; tkt, transketalose; tal,
transaldolase. Modified from Fraenkel (1996).
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transaldolase (tkt-tal) to form the four-carbon erythrose-4-phosphate (Horecker,
2002). M. tuberculosis has complete glycolytic and pentose phosphate pathways;
transposon mutants in tkt and tal have been shown to be impaired for growth in

vitro (Sassetti et al., 2003).
6-phosphogluconate can be oxidized to glyceradehyde-3-phosphate and
pyruvate via the Entner-Doudoroff pathway (EDP). The two unique EDP genes
are edd, encoding 6-P-gluconate hydratase, and eda, coding for 2-keto-3-deoxy6-P-gluconate aldolase (Fraenkel, 1996; Peekhaus and Conway, 1998). The
combined action of the two enzymes converts a phosphate hexose into pyruvate
and phosphotriose. Recent examination of hyperthermophilic archaea and
bacteria has led Romano and Conway (1996) to conclude that the EDP is an
older route of sugar dissimilation than the EMP. Based on the presence of
gluconeogenesis via a “reversed” EMP route, but the lack of the traditional EMP
in ancient organisms, they suggest that the EDP was the original catabolic
pathway, with the “reversed” EMP originally serving an anabolic role; the EMP
become a catabolic pathway with the evolution of phosphofructokinase. In
pathogenic mycobacteria, however, there is no evidence for the existence of the
EDP as homologs of edd and eda are missing (Muñoz-Elías and McKinney, 2006).
Figure 2.3 shows the pathways for glucose degradation in archaea, which
occurs via variants of the EMP and EDP (Verhees et al., 2003). As depicted, the
EDP is present in an altered form from the EDP in E. coli; the reduction of
glyceraldehyde-3-phosphate to 3-phosphoglycerate can be accomplished in a
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Figure 2.3. Glucose degradation in archaea via variants of the Embden-Meyerhof
pathway (EMP) and Entner-Doudoroff pathway (EDP). Unique genes are: gapor,
glyceraldehyde-3-phosphate ferredoxin oxidoreductase; gapn, non-phosphorylating
glyceraldehyde-3-phosphate dehydrogenase (NAD+ dependent); gdh, gluconate
dehydratase; kald, 2-keto-3-deoxy-gluconate aldolase; kgdK, 2-keto-3-deoxy-gluconate
kinase; gad, glyceraldehyde dehydrogenase; glcK, glycerate kinase. GAPN catalyzes the

phosphate-independent, single-step oxidation of glyceraldehyde-3-phosphate to 3phosphoglycerate, thus differing from GAPDH. KGDP, 2-keto-3-deoxy-phosphogluconate;
KGD, 2-keto-3-deoxy-gluconate; GA, glyceraldehyde; GAP, glyceradehyde-3-phosphate;
PGP, glycerate-1,3-bisphosphate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate;
PEP, phosphoenolpyruvate. Modified from Verhees et al. (2003).
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reaction

catalyzed

by

GAPOR

(glyceraldehyde-3-phosphate

ferredoxin

oxidoreductase) and GAPN (non-phosphorylating glyceraldehyde-3-phosphate
dehydrogenase, NAD+ dependent enzyme). Also, gluconate is converted to 2keto-3-deoxy-phosphogluconate by the enzymes GDH and KGDK in a two-step
mechanism, obviating the need for the reaction catalyzed in eubacteria by EDD.
KGD can separately be oxidized to 2-phosphoglycerate as well.
Unlike the variant EMP and EDP pathways used by archaea and
eubacteria/eukarya, the gluconeogenic pathway is conserved in both (Figure
2.4), consistent with the idea that gluconeogenesis is an ancient pathway, while
the catabolic role of the EMP is more recent (Romano and Conway, 1996). Two
enzymes unique to the gluconeogenic pathway are fructose-1,6-bisphosphatase
(fbp) and PEP synthase (pps). E. coli mutants lacking fbp cannot grow on
gluconeogenic substrates such as acetate and dicarboxylic acids (Fraenkel and
Horecker, 1965). In M. tuberculosis, the gluconeogenic dephosphorylation of
fructose-1,6-bisphosphate

is

catalyzed

by

the

class

II

fructose-1,6-

bisphosphatase encoded by the glpX gene (Movahedzadeh et al., 2004).

M. tuberculosis does not possess a pps homolog; instead, pyruvate
phosphate dikinase (ppdK) catalyzes the same conversion. M. smegmatis has a
homolog of pps, but not ppdK. Aside from phosphorylation of pyruvate,
phosphoenolpyruvate

(PEP)

can

be

generated

by

decarboxylation

of

oxaloacetate, catalyzed by PEP carboxykinase (PCK). E. coli strains lacking PCK
cannot grow on the TCA cycle intermediates malate, fumarate, or oxaloacetate
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Figure 2.4. Gluconeogenesis. Found in both bacteria/eukarya and archaea, this
pathway reduces pyruvate to fructose-6-phosphate, which can be further converted to
glucose-6-phosphate or xululose-5-phosphate (or ribose-5-phosphate) via the pentose
phosphate pathway (PPP). Pentose sugars are used for nucleotide biosynthesis.
Enzymes unique to gluconeogenesis are: fbp, fructose-1,6-bisphosphatase; pps,
phosphoenolpyruvate synthase; ppdk, pyruvate phosphate dikinase.
Modified from Verhees et al. (2003).
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(Anderson and Wood, 1969). PCK is encoded by the pckA gene in M.

tuberculosis; its importance for mycobacterial survival in vivo was recently
suggested by the demonstration that pckA-deficient M. bovis BCG is attenuated
for virulence in mice and macrophages (Liu et al., 2003). M. smegmatis also
possesses a single copy of pckA. We have isolated pckA-deficient transposon
mutants with PCK deficiency, which fail to grow on acetate or palmitate (an
even-chain fatty acid) or succinate (TCA cycle intermediate) as the sole carbon
substrates (L. Merkov and A. Upton, unpubl. observations).
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2.3. Fatty acid degradation
When fatty acids are used as the carbon source, they are converted to acetylCoA via the β-oxidation cycle (Figure 2.5). Each turn of the β-oxidation cycle
generates one molecule of FADH2 and one molecule of NADH, which can be used
for production of ATP, making growth on fatty acids more energetically favorable
than growth on acetate alone (Clark and Cronan, 1996). While E. coli possesses
a small number of genes involved in fatty acid degradation, all mycobacterial
genomes exhibit an extensive degree of duplication of the fad genes, as shown
in Fig. 2.5. This gene expansion is not limited to pathogenic species, as M.

smegmatis contains a comparable number of fad genes.
The E. coli fadL gene, which is essential for long chain (> C12) fatty acid
transport (Black, 1988; 1991), has no annotated homologs in mycobacteria. This
may be explained by the fact that FadL resides in the outer membrane of E. coli,
and is responsible for transport of long chain fatty acid in the periplasmic space,
while medium-length and short chain fatty acids may diffuse freely through the
outer membrane. FadD then activates fatty acids by linking them to coenzyme-A
(CoA), for which it requires free pools of both CoA and ATP; the activation of
fatty acids renders their transport unidirectional (DiRusso and Black, 2004).
Mycobacteria, on the other hand, have no outer membranes; thus, fatty acids
may simply diffuse to, and through, the plasma membrane, where they would be
activated by FadD proteins. The lipid-rich outer wall of mycobacteria might be
permissive for diffusion of fatty acids toward the plasma membrane.
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Figure 2.5. Fatty acid β-oxidation cycle. E. coli (ECO) and M. tuberculosis (MTB) genes
(italicized) and enzymes are listed. Reproduced from Muñoz-Elías and McKinney (2006).
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The fatty acid CoA synthase (FACS) encoded by fadD was originally identified by
Overath et al. (1969). FACS catalyzes the synthesis of fatty-acyl CoA through the
formation of a fatty acyl-AMP intermediate and the hydrolysis of ATP to yield
pyrophosphate. All FACS proteins contain two canonical regions, the ATP-AMP
motif, and the FACS motif. While FadL is specific for the transport of long-chain
fatty acids, the E. coli FACS activates fatty acids varying in length from C6:0 to
C20:4, with the highest specificity for C14:0 to C18:0 (Black and DiRusso, 1993).
The products of the 36 M. tuberculosis fadD genes can function as FACL
(fatty acyl-CoA ligases) or FAAL (fatty acyl-AMP ligases) (Trivedi et al., 2004).
While the FACL form fatty acyl-CoAs of different length, the FAAL form fatty acylAMPs. The genes encoding FAAL are located next to polyketide synthesis (PKS)
genes; FAAL activate fatty acids as acyl-adenylates and then transfer them onto
the PKS. Disruption of fadD28 (FAAL), in M. tuberculosis blocked the synthesis
and export of a cell wall-associated lipid, phthiocerol dimycocerosate (PDIM); the
PDIM-deficient mutants were attenuated in mice (Cox et al., 1999).
The FACL proteins demonstrate remarkable substrate tolerance in
generating fatty acyl-CoAs from the corresponding fatty acids (Arora et al.,
2005). The combination of the large number of genes encoding FACL and the
substrate promiscuity of individual FACL enables mycobacteria to activate a
tremendous variety of fatty acids for biosynthesis or catabolism. These acyl-CoAs
can enter the β-oxidation cycle as substrates for acyl-CoA dehydrogenase (FadE),
which carries out the first repetitive step of β-oxidation (Figure 2.5).
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The enoyl-CoA hydratase and 3-hydroxyacyl-CoA dehydrogenase activities
of the β-oxidation cycle in E. coli are carried out by the product of fadB. M.

tuberculosis and M. smegmatis possess over twenty genes predicted to encode
enzymes with one of the two activities. The fadA genes, whose products catalyze
the last step of the cycle, the removal of a molecule of acetyl-CoA, comprise the
smallest group of cycle participants. A shortened fatty acyl-CoA molecule then
reenters the cycle by binding to FadE, while acetyl-CoA enters the TCA cycle.
Short-chain fatty acids (C4-C6) are assimilated differently by E. coli. E. coli
FACS cannot activate fatty acids shorter than C6 so the induction of a new set of
genes, the atoADBC operon, is required for growth on acetoacetate and butyrate
(Figure 2.6). The atoADBC operon is repressed by FadR; derepression, as well as
the expression of a positive regulator encoded by atoC, results in the expression
of the structural genes atoADB (Pauli and Overath, 1972). FadR repression is
relieved through binding of an activated fatty acyl-CoA molecule and thus
requires FACS activity (DiRusso and Black, 2004; Clark and Cronan, 1996). DNA
binding by FadR is strongly inhibited by fatty acyl-CoA esters, with C16-C18 acylCoAs showing the lowest Ki values. FadR dimers act as both repressors and
activators, inhibiting transcription of the fad and ato genes, while activating the
expression of the fatty acid biosynthesis genes fabA and fabB. FadR also
activates iclR, which encodes a transcriptional repressor of the glyoxylate shunt
genes; FadR can thus inhibit the expression of both the β-oxidation genes, which
produce acetyl-CoA, and the glyoxylate shunt genes (Gui et al., 1996).

21

Figure 2.6. Pathways for assimilation of short-chain fatty acids. The atoABCD operon
is required for catabolism of C4-C6 fatty acids in E. coli. The transcription of atoA, atoB,
and atoD is under the control of regulators encoded by atoC (activator) and fadR
(repressor). The mycobacterial scoBA genes have some homology to atoAD, while fadA
genes have some similarity to atoB, which suggests they may play a role similar to the
ato genes when mycobacteria are grown on C4-C6 fatty acids (butyrate, valerate and
hexanoate). Modified from Clark and Cronan (1996).
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The scoBA genes of M. tuberculosis have some homology to atoAD, while

fadA genes have similarity to atoB. It is tempting to speculate that the scoBA
genes participate in the metabolism of short-chain fatty acids; however, there is
as yet no functional evidence to supports this hypothesis. On the other hand,
neither the M. tuberculosis nor the M. smegmatis genome contains an obvious
homolog of fadR. In fact, it is not known if, and how, fad genes are regulated in
mycobacteria. We have consistently observed a slight lag in the growth of M.

smegmatis in minimal media containing butyrate or hexanoate as sole carbon
sources; this lag was not seen in the growth of M. smegmatis in media
containing acetate, propionate, or valerate as carbon sources; these data will be
presented in detail in the Results section (Chapter 3).
The lack of an obvious FadR homolog in mycobacteria does not preclude
the possibility that some transcriptional factors are under the negative or positive
control of activated fatty acids, such as fatty acyl-CoAs or fatty acyl-AMPs. The
presence of a significant number of hypothetical genes predicted to encode for
transcriptional regulators, as well as the existence of numerous fad and fab
promoter regions to analyze computationally, suggests that any potential
regulators of the fad and fab genes will have to be discovered experimentally.
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2.4. Acetyl-CoA metabolism
The discovery of coenzyme-A (CoA) and the elucidation of its role as a carrier for
acyl groups is arguably one of the most significant biochemical discoveries of the
previous century (Bentley, 2000). As early as the 1870s, “reactive” C2 units were
implicated in fatty acid biosynthesis; in 1907, Raper proposed a role for active C2
units by stating: “The formation of fatty acids in animals, from carbohydrates,
and the occurrence of natural fats such as butter, of all the fatty acids containing
an even number of carbon atoms, from two to twenty, suggest that their fatty
acids are produced by the condensation of some highly reactive substance
containing two carbon atoms and formed in the decomposition of sugar” (Raper,
1907). Rittenberg and Bloch (1945) demonstrated the utilization of acetate
carbons for fatty acid synthesis in tissues and suggested that “fatty acids are
synthesized by condensation of C2 units” with a CO → CH2 conversion.
Investigating lipid catabolism in 1904, Knoop fed dogs fatty acids carrying
a terminal phenyl group and analyzed the compounds excreted in the urine; such
“tracer” experiments led him to conclude that “fatty acid catabolism required the
oxidation at the β carbon with loss of C2 units” (quoted in Bentley, 2000). The βoxidation theory was confirmed when Schoenheimer and Rittenberg (1937)
observed in animals the conversion of C18 stearic acid to C16 palmitic acid to
C14 myristic acid and C12 lauric acid. They proposed that the product was acetic
acid or a functional derivative, but the structure of the “reactive C2” unit would
remain a mystery it was solved in the 1940s by Fritz Lippman (Lippman, 1954).
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Amino Acids

Acetaldehyde
Ethanol

Fatty Acids

Tricarboxylic Acid Cycle
Glyoxylate Shunt

Acetyl-CoA

Glycolysis
Pi

AMP
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PPi
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Figure 2.7. Acetyl-CoA in intermediary metabolism. The reactions that activate acetate
to acetyl-CoA are detailed. Abbreviated enzymes: PTA, phosphotransacetylase; ACKA,
acetate kinase; ACS, AMP-forming acetyl-CoA synthase. Modified from Wolfe, 2005.
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Acetyl-CoA can be generated from pyruvate, the end product of glycolysis,
via the action of pyruvate dehydrogenase (PDH) (Figure 2.7). As mentioned in
the previous subsection, each turn of the β-oxidation cycle releases a molecule of
acetyl-CoA. Acetyl-CoA can be generated directly from acetate, by the two-step
phosphotransacetylase (PTA) and acetate kinase (ACK) pathway, or directly by
acetate CoA synthase (ACS). ACK phosphorylates the acetate molecule, and then
PTA replaces the reactive phosphate group with coenzyme A. ACS forms the
acetyl-CoA molecyle via an acetyl-AMP intermediate (Wolfe, 2005).
Depending on the organism’s metabolic needs, acetyl-CoA can be oxidized
by the TCA cycle, where it is converted into two CO2 molecules and water. When

E. coli cells are grown in high levels of glucose, they secrete acetate in the media
through the PTA-ACKA pathway. When the supply of glucose is exhausted, they
“switch” to metabolizing acetate back to acetyl-CoA using ACS (Holms, 1996).
Deletion of the pta-ackA genes still allows E. coli to grow on acetate using ACS; a
mutant lacking both pathways, however, is completely unable to utilize acetate
(Kumari et al., 1995). M. tuberculosis and M. smegmatis have homologs of all
three genes. Transposon mutants in the acs gene of M. smegmatis are unable to
grow on agar plates containing a low concentration (0.1%) of acetate as the sole
carbon. However, when the acetate concentration is increased to 0.5% or 1.0%,
the acs mutants grow well, implying that acs is more efficient at scavenging low
amounts of acetate, which cannot be accomplished by PTA-ACK (L. Merkov,
unpubl. observations).
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2.5. Tricarboxylic Acid Cycle
Hans Adolf Krebs discovered three metabolic cycles: the ornithine cycle, the
tricarboxylic acid (TCA) cycle and the glyoxylate cycle (Kornberg, 2000). During
his work on the TCA cycle, Krebs built on early experiments done by a Hungarian
biochemist, Albert Szent-Gyorgyi, who had studied the processes through which
carbohydrates, proteins, and fats were oxidized to CO2 and water. Szent-Gyorgyi
had discovered several C4 salts that were oxidized in tissues—succinate to
fumarate, fumarate to malate, and malate to oxaloacetate—but he did not look
for a circular pathway of oxidation (Kornberg, 2000).
Krebs envisioned a circle, however, when he realized that adding pyruvate
to tissues generated succinate, and that citrate could be formed from
oxaloacetate if pyruvate was added. Krebs proposed the cycle in a paper that
was rejected by Nature; as acetyl-CoA was not known at the time, he suggested
that a triose was formed from oxaloacetate that reacted with pyruvate to form
citrate (Krebs and Johnson, 1937). Lippman’s discovery of acetyl-CoA about a
decade later suggested to Krebs the answer to his conundrum (Figure 2.8).
The TCA cycle has two roles: the oxidation of acetyl-CoA to carbon dioxide
and water, and the production of precursors for amino acid, porphyrin, and
cofactor biosynthesis (Cronan and LaPorte, 1996). The oxidation of acetyl-CoA
generates two molecules of NADH, one NADPH, and one FADH2, which in turn
are used for ATP production via respiration. The two carbons that enter the TCA
cycle from acetyl-CoA are sequentially lost as two carbon dioxide molecules.
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Figure 2.8. Tricarboxylic acid (TCA) cycle (top) and glyoxylate cycle (bottom). The net

effect of one turn of the TCA cycle is conversion of one molecule of acetate and two
molecules of O2 into two CO2 molecules. The glyoxylate cycle bypasses the two CO2
release steps, thus converting two acetates and half an O2 molecule into succinate.
Modified from Cronan and LaPorte (1996).
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The highest induction of the TCA cycle genes in E. coli is observed during aerobic
growth on acetate or fatty acids. Such conditions, however, necessitate the
induction of the glyoxylate shunt genes aceA and aceB encoding the E. coli
isocitrate lyase and malate synthase, respectively, so that intermediates lost to
biosynthesis can be replenished (Figure 2.8, bottom). The glyoxylate shunt is
required for anaplerosis when acetate or fatty acids are the sole carbon sources;
partitioning of some of the isocitrate through the shunt allows the regeneration
of the four-carbon malate from glyoxylate and acetyl-CoA; this reaction
replenishes four-carbon intermediates used for biosynthetis purposes.
Acetyl-CoA enters the cycle in a reaction catalyzed by citrate synthase that
yields a molecule of citrate from condensation of oxaloacetate and acetyl-CoA.

M. tuberculosis has at least three citrate synthase genes (gltA1, gltA2, citA) while
M. smegmatis may have at least four (see Table 2.1). Interestingly, an M.
smegmatis transposon mutant of gltA2 has a slight growth defect on plates
containing acetate as the sole carbon (L. Merkov, unpubl. observations).
Aconitase converts citrate to isocitrate; in E. coli, the fate of isocitrate is tightly
controlled by the phosphorylation status of isocitrate dehydrogenase (IDH). If
isocitrate is converted to α-ketoglutarate, a molecule of CO2 is lost; a second CO2
molecule is lost when α-ketoglutarate is oxidized to succinyl-CoA by the αketoglutarate dehydrogenase complex (KGDH). Succinate thiokinase (sucCD)
converts succinyl-CoA to succinate, and generates a molecule of ATP. The KGDH
genes (sucAB) and sucCD form an operon in E. coli.
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Gene

pyk

Function
Pyruvate kinase

H37Rv
1617

pca

Pyruvate carboxylase

2967c

ppc*
pck
ppdK
pps*
mez
gltA1

PEP carboxylase
PEP carboxykinase
Pyruvate phosphate dikinase
PEP synthase
Malic enzyme
Citrate synthase

(none)
0211
1127
(none)
2332
1131

gltA2

Citrate synthase

0896

acn
icl1
icl2
prpB*

Aconitase
Isocitrate lyase 1
Isocitrate lyase 2
Methylisocitrate lyase

1475c
0467
1915/16
(none)

glcB
kgd
sucB
sucC
sucD
sdhA
sdhB
sdhC
sdhD
sdhA2
sdhB2
frdA
frdB
frdC
frdD
fum
mdh
mqo
sfcA*
maeB*
gcvB

Malate Synthase
α-Ketoglutarate carboxylase
Pyruvate dehydrogenase E2
Succinyl-CoA synthase, beta
Succinyl-CoA synthase, alpha
Succinate dehydrogenase A
Succinate dehydrogenase B
Succinate dehydrogenase C
Succinate dehydrogenase D
Succinate dehydrogenase A2
Succinate dehydrogenase B2
Fumarate reductase A
Fumarate reductase B
Fumarate reductase C
Fumarate reductase D
Fumarase
Malate dehydrogenase
Malate-quinone oxidoreductase
Malic enzyme, NAD linked
Malic enzyme, NADP linked
Glycine dehydrogenase

1837c
1248c
2215
0951
0952
3318
3319
3316
3317
0248c
0247c
1552
1553
1554
1555
1098c
1240
2852c
(none)
(none)
1832

MSMEG
3237
0148
2410
6609
3107
0246
(none)
3938
(none)
6608
4040
5650
5654
3151
0904
3713
6607
6818
3646
5037
4286
5503
5502
1667
1666
1669
1668
0408
0407
(none)
(none)
(none)
(none)
5225
(none)
2614
(none)
5043
3648

Table 2.1. Homologs of M. tuberculosis genes in M. smegmatis. Metabolic pathway
genes from H37Rv were compared to the recently annotated M. smegmatis genome on
TIGR’s website (http://tigrblast.tigr.org/cmr-blast/). If a gene was not found in H37Rv,
the sequence of the E. coli protein was used for searches; that gene is indicated in the
table with (*). sucA (Rv1248c) has been renamed kgd, per Tian et al. (2005).
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M. tuberculosis has a different mechanism of generating succinate from αketoglutarate (Tian et al., 2005). KGDH activity is missing; α-ketoglutarate is first
converted to succinic semialdehyde in a reaction catalyzed by α-ketoglutarate
decarboxylase (KGD, encoded by rv1248c), and succinic semialdehyde is further
oxidized to succinate by two succinic semialdehyde dehydrogenases (SSADH)
encoded by gabD1 (rv0234) and gabD2 (rv1731). KGD appears to be important
for in vitro growth (Sassetti et al., 2003). M. tuberculosis would need to generate
succinyl-CoA, needed for heme biosynthesis, either from succinate by succinylCoA synthetase, or from propionyl-CoA by propionyl-CoA carboxylase and
methylmalonyl-CoA mutase (Munoz-Elias and McKinney, 2006).
Interestingly, Tian et al. (2005) did not detect KGDH activity in M. bovis or

M. smegmatis. This suggests that the KGDH bypass by the combined activities of
KGD and SSADH may be a general feature of mycobacteria. Analysis of the M.

smegmatis genome revealed that M. smegmatis does possess a homolog of kgd
(rv1248c), annotated as MSMEG5037. When testing protein extracts from M.

tuberculosis, M. bovis, and M. smegmatis for TCA cycle enzyme activities, Tian et
al. (2005) detected malate dehydrogenase (MDH) activity in M. tuberculosis and
M. bovis, but did not detect it in M. smegmatis. As shown in Table 2.1, searches
with M. tuberculosis mdh failed to reveal a homolog in M. smegmatis, suggesting
the saprophyte may rely solely on MQO, malate-quinone oxidoreductase, to
oxidize malate to fumarate. M. smegmatis lacks a homolog of the M. tuberculosis
malic enzyme (mez) but has a protein similar to the E. coli malic enzyme (maeB).

31

Figure 2.9. Tricaboxylic acid cycle and associated anaplerotic pathways. CIT, ACN and
IDH catalyze the oxidative branch (blue arrows), while MDH/MQO, FUM, FRD/SDH and
SUC comprise the reductive branch (red arrows) of a bifurcated cycle. Bifurcation occurs
when bacteria grow aerobically in excess glucose or anaerobically on any carbon source.
Anaplerosis (green arrows) is achieved by PPC or PCA during growth on sugars or by ICL
and MLS during growth on acetate or fatty acids. TCA cycle and glycolysis intermediates
that are also used for biosynthetic purposes are boxed. See Table 2.1 for gene names.
BOC, β-oxidation; MCC, methylcitrate cycle. Reproduced from Muñoz-Elías and McKinney
(2006)
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2.6. Anaplerosis
The term “anaplerosis” was coined by Hans Kornberg to describe the “filling up”
reactions that replenish intermediates in central metabolic pathways (Kornberg,
2003). Since TCA cycle intermediates are used as precursors for biosynthetic
reactions, bacteria must replenish them through reactions complementary to the
TCA cycle (Figure 2.9). The first anaplerotic enzyme discovered by Kornberg was
PEP carboxylase (PPC), which produces oxaloacetate from PEP. E. coli ppc
mutants are auxotrophic for succinate when grown on sugars but can grow on
acetate, lactate, or malate without supplementation (Kornberg, 1966). Residual
growth of ppc mutants on sugars correlates with expression of the glyoxylate
shunt (Peng et al., 2004), likely due to suppressor mutations that increase
expression of the glyoxylate shunt genes (Sauer and Eikmanns, 2005).
Although Corynebacterium glutamicum possesses a functional PPC,
carboxylation of pyruvate to oxaloacetate, mediated by PCA, appears to be the
main anaplerotic pathway (Peters-Wendisch et al., 1998). Similarly, Bacillus

subtilis pca mutants are unable to grow on substrates that enter glycolysis
upstream of pyruvate unless supplemented by TCA cycle intermediates
(Diesterhaft and Freese, 1973). PPC is the more widely distributed anaplerotic
enzyme, as few bacteria aside from C. glutamicum and B. subtilis use PCA
exclusively for anaplerosis (Sauer and Eikmanns, 2005).
PCA appears to be the main anaplerotic pathway in M. tuberculosis, as

ppc is missing (Table 2.1), and pca mutants grow poorly on plates containing
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both dextrose and glycerol as carbon sources (Sassetti et al., 2003). In constrast,

M. smegmatis has a homolog of the E. coli ppc gene and two homologs of the M.
tuberculosis pca gene. A recent report implicated PCA as the major anaplerotic
enzyme in M. smegmatis (Mukhopadhyay and Purwantini, 2000), but additional
experiments are needed to reconcile the biochemical data in this report with the
existence of a ppc gene in addition to two pca genes. pca appears to be the only
anaplerotic gene in M. bovis and M. leprae, as determined by genomic analysis.
When grown on acetate or fatty acids instead of carbohydrates, E. coli
depends on the glyoxylate shunt enzymes isocitrate lyase and malate synthase
for anaplerosis (Kornberg and Krebs, 1957; Kornberg, 1966). The enzymes of the
glyoxylate shunt in E. coli are encoded by aceA and aceB, respectively, and they
reside in an operon with a third gene, aceK, which encodes IDH kinasephosphatase, which is involved in regulating carbon flow through the shunt by
phosphorylation-mediated inactivation of IDH (Cronan and LaPorte, 1996).
Expression of the aceBAK genes is induced by acetate or fatty acids; it is under
the direct negative control of IclR and indirect negative control of FadR; FadR
exerts inhibition by enhancing the expression of the iclR gene (Gui et al., 1996).
IclR inhibition of the aceBAK operon is relieved by PEP (Cortay et al., 1991) while
FadR repression is obviated by FadR interaction with fatty acyl-CoA molecules. E.

coli possesses a second malate synthase, encoded by glcB, which functions in
growth on glyoxylate and glycolate as sole carbon sources (Molina et al., 1994).
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Some bacteria can grow on C2 compounds as sole carbon sources
independent of isocitrate lyase activity, due to alternative anaplerotic pathways.

Streptomyces collinus uses crotonyl-CoA reductase (CCR), which catalyzes the
conversion of two acetyl-CoA molecules to butyryl-CoA; ccr mutants exhibit
reduced growth on acetate. Disruption of a second gene, meaA, which may
encode an enzyme similar to isobutyryl-CoA mutase, also impairs growth of S.

collinus on acetate. Interestingly, S. collinus can use isocitrate lyase to grow on
fatty acids but not on acetate, which requires induction of ccr and meaA (Han
and Reynolds, 1997). Recent evidence suggests the existence of a third pathway
for assimilation of acetate in S. cinnamonensis, which is capable of growth on
acetate even if the glyoxylate cycle and butyryl-CoA pathway are mutationally
inactivated (Akopiants et al., 2006).
Most methylotrophic bacteria also lack isocitrate lyase and convert acetylCoA to glyxolyate through butyryl-CoA and propionyl-CoA intermediates.
Korotkova et al. (2002) demonstrated that the acetyl-CoA assimilation cycle in

Methylobacterium extorquens is linked to the polyhydroxybutyrate cycle and the
serine cycle for assimilation of C1 compounds. Two acetyl-CoA molecules are
converted to crotonyl-CoA → propionyl-CoA → succinyl-CoA → malyl-CoA, which
is broken down to glyoxylate and acetyl-CoA. Glyoxylate then enters the serine
cycle, which assimilates C1 and C2 compounds. This complex cycle regenerates
glyoxylate in the absence of isocitrate lyase.
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2.7. Glyoxylate assimilation pathways
The reacton catalyzed by isocitrate lyase produces succinate and glyoxylate from
isocitrate. Malate synthase condenses glyxoxylate with acetyl-CoA to produce
malate. As mentioned already, E. coli has two malate synthases, which are
induced by acetate and fatty acids (20 fold induction of aceB) or by glycolate
(1,000 fold induction of glcB) (Clark and Cronan, 1996). Malate synthase A
(aceB) is needed for growth on acetate as the sole carbon source; malate
synthase G (glcB) is dispensable for growth on glycolate or glyoxylate, as
glyoxylate induces glyoxylate carboligase (gcl) (Ornston and Ornston, 1969).
Glyoxylate carboligase activity was initially described by Krakow and
Barkulis (1956) as the conversion of glyoxylate to hydroxypyruvate. Biochemical
characterization of the enzyme indicated that GCL converts two glyoxylates into a
molecule of tartronate semiladehyde, with the release of carbon dioxide (Krakow

et al., 1961) (Figure 2.10). The purified enzyme is a FAD flavoprotein requiring
thiamine pyrophosphate and magnesium for activity (Gupta and Vannesland,
1964). The tartronate semialdehyde is reduced to d-glycerate, which is converted
by glycerate kinase to 3-phosphoglycerate, an EMP intermediate (Kornberg and
Sadler, 1960; Kornberg and Gotto, 1961; Hansen and Hayashi, 1962). Tartronate
semialdehyde can be converted to hydroxypyruvate by a hydroxypyruvate
isomerase, but the reduction to glycerate represents the relevant conversion for
anaplerotic purposes. Malate synthase G does not play a role in this pathway
(Ornston and Ornston, 1969).
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Figure 2.10. Glyoxylate utilization pathways in bacteria. Glyoxylate can be generated
from glycolate by glycolate oxidase (GOX, #1 above), from isocitrate by isocitrate lyase
(ICL, not shown), or other pathways in ICL-negative bacteria. It can then be utilized via
the glyoxylate shunt TCA cycle (5, 6, 11); d-glycerate pathway (2, 3, 4); or erythro-βhydroxyaspartate pathway (7, 8, 9). Numbered enzymes: 2, glyoxylate carboligase; 3,
tartronic semialdehyde reductase; 4, glycerate kinase; 5, malate synthase; 6, malate
dehydrogenase; 7, glycine dehydrogenase; 8, β-hydroxyaspartate aldolase; 9, βhydroxyaspartate dehydratase; 10, glyoxylate reductase; 11, citrate synthase. Modified
from Kornberg and Morris (1965) and Ornston and Ornston (1969).
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The glcB gene is unlinked to either the aceBAK operon or gcl region in E. coli. gcl
maps at min. 12 on the E. coli chromosome, while glcAB is at min. 64 and

aceBAK is at min. 90 (Clark and Cronan, 1996). The gcl gene was identified by
Chang et al. (1993); subsequent work by Cusa et al. (1999) demonstrated the
presence of both gcl, glxR (encoding the tartronate semialdehyde reductase),
and glxK (glycerate kinase). These genes are grouped with genes involved in
allantoin metabolism; allantoin is a product of purine degradation and can be
used as a nitrogen source by E. coli. Ashiuchi and Misono (1999) located the
hydrohypyruvate isomerase (hyi) gene between gcl and glxR. The glc locus,
besides the glcB gene, also contains glcE and glcD, encoding glycolate oxidases,

glcF, an iron-sulfur oxidase, and the positive regulator glcC (Pellicer et al., 1996).
Micrococcus denitrificans does not possess glyoxylate carboligase activity
but can grow on glycolate or glyoxylate as the sole carbon source by using the βhydroxyaspartate pathway (Kornberg and Morris, 1965). A molecule of glyoxylate
is first reduced to glycine by glycine dehydrogenase; then β-hydroxyaspartate
aldolase condenses one glyoxylate and one glycine to form a C4 unit, βhydroxyaspartate, which is next converted to oxaloacetate by β-hydroxyaspartate
dehydratase (Figure 2.10). Oxaloacetate can be converted to PEP by the PEP
carboxykinase (PCK) to generate C3 units and acetyl-CoA. While this pathway
completely bypasses the d-glycerate pathway, it has been described only in M.

denitrificans and in Paracoccus denitrificas, which also possesses a D-3hydroxyaspartate aldolase (Liu et al., 2003).
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2.8. The in vivo importance of the glyoxylate cycle
The first study that in retrospect would suggest a role for the glyoxylate cycle in
the ability of intracellular bacteria to survive in the tissues of infected hosts
(Segal and Bloch, 1956) was published one year before the glyoxylate cycle was
described in bacteria by Kornberg and Krebs (1957). Using a novel method to
isolate pathogenic mycobacteria from the lungs of infected mice, Segal and Bloch
(1956) compared their ability to respire carbohydrates, benzoates, and fatty
acids to the respiratory profile of bacteria grown in vitro. Importantly, they
noticed that while the in vitro-grown bacteria rapidly oxidized glucose, glycerol,
pyruvate and acetate, as well as sodium salicylate and fatty acids, bacteria
recovered from infected tissues had a respiratory response only to salicylic acid
and fatty acids. The long-chain oleic acid (C18) was oxidized more readily than
heptanoic acid (C7) or octanoic acid (C8) (Segal and Bloch, 1956). These
observations suggested that the metabolism of bacteria in the lungs was adapted
for catabolism of fatty acids.
Kanai and Kondo (1974) measured fatty acid oxidation in mycobacteria
grown in vivo as well. Kondo et al. (1970) demonstrated an association between
lipids and bacilli harvested from the lungs of mice, by developing an in vitro
system of lechitin-cholesterol liposomes to study lipid-mycobacteria interactions
and then showing that bacilli could metabolize liposomes and release fatty acids.

In vitro models of non-replicating persistence (NRP), which aimed to
imitate the chronically infected lung environment, also detected the induction of
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enzymes to utilize alternative energy sources (Wayne and Sohaskey, 2001).
Murthy et al. (1973) reported a decrease in the activity of TCA cycle enzymes in
aging M. tuberculosis cultures, combined with a five-fold induction of isocitrate
lyase activity. Wayne and Lin (1982) saw a comparable induction of isocitrate
lyase (ICL) activity in the NRP model, but no change in malate synthase (MLS)
activity. Instead, they observed a ten-fold induction in glycine dehydrogenase
activity, which catalyzes the reductive amination of glyoxylate to glycine while
oxidizing NADH to NAD+ (Goldman and Wagner, 1962). Wayne and Lin (1982)
proposed that the main purpose of glyoxylate → glycine reduction was the
replenishment of NAD+ to support microaerobic metabolism. The gene encoding
this glycine dehydrogenase activity has not been identified; a likely candidate,

gcvB, appears to be essential in M. tuberculosis (Sassetti et al., 2003).
The importance of ICL for the in vivo survival and persistence of M.

tuberculosis was demonstrated by genetic studies of bacteria lacking icl1 or icl2
or both genes (McKinney et al., 2000; Munoz-Elias and McKinney, 2005). An M.

tuberculosis ∆icl1 mutant successfully established infection in the lungs of mice,
but failed to persist in the face of the host immune response as the number of
∆icl1 bacteria in the lungs decreased over time (McKinney et al., 2000). An M.

tuberculosis ∆icl1∆icl2 mutant failed to replicate in the lungs of mice, and was
cleared from the lungs by two weeks post-infection. ∆icl1∆icl2 bacteria were also
avirulent in mice lacking the macrophage-activating cytokine interferon-γ, which
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are exquisitely sensistive to wild-type M. tuberculosis, demonstrating that ICL is
absolutely required for in vivo survival (Munoz-Elias and McKinney, 2005).
ICL activity has been implicated in the virulence of a number of other
bacterial and fungal pathogens (Lorenz and Fink, 2002; Idnurm and Howlett,
2002; Wang et al., 2003; Fang et al., 2005; Wall et al., 2005). Similarly, loss of
MLS activity has been shown to attenuate pathogenicity in Rhodococcus fascians
(Vereecke et al., 2002) and Stagonospora nodorum (Solomon et al., 2004). Thus,
either glyoxylate shunt enzyme, ICL or MLS, could be a viable target for drug
development. The existence of two ICL isoenzymes in M. tuberculosis
necessitates a dual-specific inhibitor that is effective against both. Muñoz-Elías
and McKinney (2005) showed that 3-nitropropionate inhibits both ICLs, implying
that the development of one drug targeting both enzymes might be possible.
Availability of the X-ray crystal structures of ICL1 (Sharma et al., 2000) and MLS
(Smith et al., 2003) should facilitate drug development.
The crystal structure of M. tuberculosis MLS suggests that it might be a
more attractive drug target than ICL1/ICL2. The active site in MLS is at the end
of ~ 15 angstrom tunnel which accommodates coenzyme-A; this tunnel appears
to be an attractive target for inhibitor binding (Smith et al., 2003). Attempts to
delete the M. tuberculosis glcB gene encoding MLS have been unsuccessful so
far, suggesting that glcB might be essential (Muñoz-Elías, 2005). We decided to
evaluate the role of MLS in mycobacterial metabolism using the saprophyte M.

smegmatis, a non-pathogenic relative of M. tuberculosis, as a model system.
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CHAPTER 3
Studies of the Glyoxylate Shunt in M. smegmatis
3.1. Deletion of the malate synthase gene (glcB) in M. smegmatis
Mycobacteria, unlike E. coli, possess only one gene encoding malate synthase
(MLS); the protein encoded by it is more homologous to malate synthase G than
malate synthase A. The MLS protein [2.3.3.9] of M. smegmatis is encoded by the

glcB gene and is annotated as MSMEG3646 in The Institute of Genomic Research
(TIGR) Comprehensive Microbial Resource (CMR) database. The M. smegmatis
MLS has 732 amino acids, 9 fewer than the M. tuberculosis MLS; the two
proteins share 80 percent identity and 86 percent similarity.
The M. smegmatis glcB gene was deleted by homologous recombination,
using a two-step counter-selection method (Figure 3.0). An internal 1.9 kb MscI
fragment was removed to create an in-frame deletion (Figure 3.1), and the
deletion was confirmed by Southern blot. The mutant was complemented with
an integrative plasmid carrying the M. tuberculosis glcB gene.
An ethanemethylsulfonate (EMS)-induced mutant carrying a point
mutation in the icl1 gene was unable to grow on agar plates containing acetate
as the sole carbon source (McKinney et al., 2000). Thus, we tested the ability of
the ∆glcB mutant to grow on minimal media plates containing glucose, shortchain fatty acids (C2-C5), and a long-chain fatty acid, methylpalmitate (C16).
Wild-type M. smegmatis forms colonies on glucose or propionate (C3) in 3 days,
acetate (C2) in 4 days, and butyrate (C4) and valerate (C5) in 5 days. Growth of
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Figure 3.0. Construction of the ∆glcB mutant. The knockout vector contains the aph
kanamycin resistance marker (Kmr), the sacB sucrose sensitivity marker (Scs), and oriC
for replication in E. coli. The glcB knockout plasmid contains the ∆glcB allele with an inframe deletion (black) in the glcB ORF (grey) and ~ 500 bp of 5’/3’ flanking sequences
(white). The ∆glcB knockout vector is electroporated into M. smegmatis; transformants
are selected on 7H10 agar + 25 µg ml-1 Km. The knockout vector does not contain a
mycobacterial ori; Kmr transformants can only arise by insertion of the plasmid in the
chromosome. Recombination between the ∆glcB allele and the chromosome upstream
(1) or downstream (2) of the internal glcB deletion results in plasmid insertion and
merodiploid formation with the configurations shown. Outgrowth of Kmr colonies in the
absence of Km allows accumulation of Kms cells in which plasmid excision from the
chromosome occurred by reverse recombination. The Kms progeny retain wild-type glcB
(3,6) or ∆glcB (4,5) in the chromosome. The excised plasmid, which cannot replicate, is
lost during successive rounds of cell division. The reverse recombinants are selected by
plating on 7H10 agar + 5% sucrose, which kills cells expressing the Scs marker.
Individual Kms Scr colonies are cloned and PCR-screened to identify ∆glcB mutants,
which are confirmed by Southern blot. Figure was kindly provided by Dr. John McKinney.
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Figure 3.1. Southern blot to confirm the deletion of the glcB gene in wild type M.
smegmatis. Selected restriction sites of the genomic region are shown for the wild-type

(top) and mutant (bottom) alleles. Genomic DNA was digested with PstI for the
Southern blot (right), and the BlpI-MscI fragment downstream of the gene was used as
a probe. Expected bands: 1,464 bp for the wild-type, 2,708 bp for the glcB mutant.
Strain 208-1-10 is a ∆glcB single mutant.
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Figure 3.2. Phenotype of the ∆glcB mutant of M. smegmatis after 5 days on minimal
media plates, with the indicated compounds (glucose, acetate, propionate, butyrate or
valerate) added as the sole carbon sources. Growth of wild type M. smegmatis (wt) and
the complemented mutant (comp) is also shown. The “comp” strain is the ∆glcB mutant
complemented with the M. tuberculosis glcB gene carried on a single-copy integrative
plasmid.
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the ∆glcB mutant on plates with various carbon substrates was therefore
inspected at day 5 (Figure 3.2). As expected, by 5 days wild type (wt) M.

smegmatis had formed colonies on all carbon sources, as had the complemented
(comp) ∆glcB mutant. The ∆glcB mutant formed colonies on agar plates
containing glucose and propionate, as we had observed with the icl1 EMS
mutant, confirming that the glyoxylate shunt is dispensable for growth of
mycobacteria on carbohydrates, and that propionate assimilation in M.

smegmatis does not require the glyoxylate shunt, in contrast to M. tuberculosis
(Muñoz-Elías et al., 2006). However, at day 5, the ∆glcB strain had failed to form
colonies on plates containing acetate or the short-chain fatty acids (SCFA)
butyrate and valerate as the sole carbon sources.
However, when the plates were inspected after 10 days of incubation,
small colonies of the ∆glcB mutant had appeared on the acetate and valerate
containing plates (Figure 3.3). After 15 days, the ∆glcB mutant formed colonies
on all substrates. Furthermore, the ∆glcB mutant could grow, albeit not robustly,
on solid media containing methylpalmitate as the sole carbon source. Thus,
unlike icl1 in M. smegmatis, glcB is not required for growth on solid media
containing acetate or SCHA as the sole carbon source, although glcB is required
for optimal growth.
MLS was also dispensable for growth on solid media containing glyoxylate
as the sole carbon source. In fact, the ∆glcB mutant grew just as well as the wild
type strain on glyoxylate plates (Figure 3.4), suggesting the existence of another,
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Figure 3.3. MLS is not essential for growth of M. smegmatis on acetate and shortchain fatty acids (butyrate and valerate); however, MLS is required for optimal growth
on these compounds as sole carbon sources. The ∆glcB mutant grows fastest on plates
with propionate, then glucose, then valerate, then acetate and then butyrate.
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Figure 3.4. MLS is dispensable for growth on acetate (top) and glyoxylate (bottom) in
M. smegmatis. While the ∆glcB mutant (left) does not grow as well as wild type on
acetate, it is indistinguishable from wild type (right) on glyoxylate.
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MLS-independent, pathway for the assimilation of glyoxylate. This alternative
pathway appears to be the dominant pathway for growth on glyoxylate as the
sole carbon source and MLS does not seem to play an essential role in it. We
considered the possibility that a second MLS might exist in M. smegmatis,
although we were not able to detect it by Southern blots. To test this possibility,
we performed enzyme assays on cell-free extracts (Figure 3.5).
The wild type, ∆glcB mutant, and complemented strains were grown in
minimal liquid media containing glucose, acetate, propionate, or short-chain fatty
acids as sole carbon sources, and the MLS activity of cell-free extracts was
measured using the method of Smith et al. (2003). In wild type M. smegmatis, a
two- to three-fold induction of MLS activity by acetate and short-chain fatty
acids, was observed. The smallest induction was observed with hexanoic acid
(C6). In contract, the MLS activity of the complemented strain (controlled by the

M. tuberculosis glcB promoter) was not induced by any carbon source.
These data agree with Smith et al. (2003), who measured the activity of
MLS in cell-free extracts of M. tuberculosis and saw no induction of enzyme
activity by acetate, palmitate, or glucose. Smith et al. (2003) observed a two-fold
increase in activity when glycolate was the sole carbon source. It appears that M.

smegmatis may regulate the expression of MLS depending on the available
carbon source, which is not the case in pathogenic M. tuberculosis. Importantly,
the cell-free extracts from ∆glcB bacteria had no detectable MLS activity,
irrespective of the amounts of substrates or protein used in the assays.
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Figure 3.5. MLS activity in cell-free extracts of wild-type M. smegmatis (wt), ∆glcB
mutant (∆g), and the ∆glcB mutant complemented with the M. tuberculosis glcB gene
(g+). Bacteria were grown to early log phase in M9 minimal media with 0.1 % glucose
(dex), acetate (ace), propionate (pro), butyrate (but), valerate (val), or hexanoate (hex)
as the sole carbon source, and MLS activity of the cell-free extracts was measured.
Three cultures were grown for each strain in each medium, and duplicate measurements
of MLS activity were obtained from each extract.
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3.2. Deletion of the isocitrate lyase genes (icl1, icl2) in M. smegmatis
The unexpected finding that MLS activity is not absolutely required for growth of

M. smegmatis on minimal media with acetate or fatty acids as the sole carbon
source led us to reconsider the anaplerotic role of the glyoxylate shunt of M.

smegmatis. Prior genetic studies of the gloxylate shunt in our laboratory were
done with a mutant obtained by chemical mutagenesis; sequencing of the icl1
gene of the mutant revealed a nonsense mutation in the coding sequence,
indicating the icl1 gene was likely inactive (A. Upton, personal communication).
However, to make certain that our studies were done with a truly ICL-null strain
of M. smegmatis, we deleted the icl1 and icl2 genes, individually and in
combination.
The icl1 gene was deleted by homologous recombination. An internal 855
bp SfoI fragment was removed, giving rise to a shortened protein lacking 285
amino acids and missing the ICL catalytic KKCGH motif (Sharma et al., 2000;
Figure 3.6). The icl1 gene was deleted in wild-type M. smegmatis and in the
∆glcB strain, which generated a mutant deficient in both steps of the glyoxylate
cycle (∆icl1 ∆glcB). Ernesto Muñoz-Elías in the laboratory had generated a ∆icl2
strain of M. smegmatis and he used the icl1 knockout construct to create a
double mutant (∆icl1 ∆icl2). All of the mutated alleles were constructed as
unmarked in-frame deletions, using the strategy depicted in Figure 3.0, in order
to avoid polar effects on expression of downstream genes.
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Figure 3.6. Southern blot to confirm the deletion of the icl1 gene in wild type M.
smegmatis, in the ∆glcB strain, and in the ∆icl2 strain. Selected restriction sites of the
genomic region are shown for the wild type (top) and mutant (bottom) alleles. The 855
bp SfoI site was removed to create an in-frame delection. Genomic DNA was digested
with FspI for the Southern blot (right), and a 677 bp region upstream of the gene was
used as a probe. Expected bands: 2,958 bp for the wild type, 2,103 bp for the mutant.
Strains 220-1-1,3,4 are ∆icl1 single mutants; 220-4-1 is the ∆icl1∆glcB double mutant;
and strain 4.4-12 is the ∆icl1∆icl2 double mutant.
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Figure 3-7. The glcB and icl2 genes are dispensable for growth on acetate and short
chain fatty acids (C4-C6). The ∆icl2 mutant is indistinguishable from wild type on all
substrates, while the ∆glcB strain has a growth delay on acetate, butyrate and valerate.
The ∆icl1 and ∆icl1∆icl2 mutant grow in liquid media supplemented with valerate (C5) as
the sole carbon source (not shown), but grow poorly on plates with valerate.
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The wild-type, ∆icl1, ∆icl2, ∆icl1 ∆icl2, and ∆glcB strains were directly
compared for growth on minimal solid media containing glucose, short-chain
fatty acids, or the long chain fatty acid methylpalmitate as sole carbon sources
(Figure 3.7). The ∆glcB single mutant was compared to the icl mutants in order
to dissect the role of the individual glyoxylate cycle enzymes in the anaplerotic
growth of M. tuberculosis on C2 substrates. Several aspects of the glyoxylate
cycle in M. smegmatis become apparent from Figure 3.7. First, the icl2 gene is
dispensable for bacterial growth on any carbon substrate; on solid media and in
liquid media, the ∆icl2 mutant behaves like the wild-type strain. Second, the
presence of a single functional copy of the icl2 gene under the control of its
native promoter fails to rescue the icl1 deficiency. However, overexpression of
the icl2 gene on a multi-copy epidomal plasmid did enable growth of the ∆icl1
and ∆icl1 ∆icl2 mutants on acetate and fatty acids (Ernesto Muñoz-Elías, personal
communication), suggesting that most likely the endogenous icl2 gene is
functional but is not expressed at sufficient levels to compensate for the loss of
the icl1 gene.
Third, the ability of M. smegmatis to grow on acetate and on fatty acids is
dependent on the icl1 gene. The ∆icl1 ∆glcB double mutant cannot grow on C2
substrates, similarl to the ∆icl1 and ∆icl1 ∆icl2 mutants (Figure 3.8). However,
the ∆icl1 ∆glcB mutant will grow on glucose or propionate, confirming that the
glyoxylate shunt is dispensable in M. smegmatis when sugars or propionate are
utilized as sole carbon sources. Lastly, it appears that M. smegmatis uses a MLS-
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Figure 3.8. The ∆icl1 ∆icl2 mutant (A) cannot grow on plates containing acetate or
the fatty acid methylpalmitate as carbon sources, while the ∆glcB mutant (B) does grow,
albeit slowly. As expected, the ∆icl1 ∆glcB mutant cannot grow on acetate or
methylpalmitate, but grows on gloucose and propionate (C).
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independent but ICL-dependent pathway for anaplerotic growth on acetate and
fatty acids. Such a pathway has not been described in mycobacteria, but it is
logical that this other gene, or set of genes, will assimilate glyoxylate. Searches
of the published mycobacterial genomes did not reveal any homologs of known
glyoxylate utilization genes, although M. tuberculosis possesses at least one
homolog of the E. coli glycolate oxidases, which convert glycolate to glyoxylate.

56

3.3. Deletion of the alanine dehydrogenase (ald) gene in M. smegmatis
The concomitant induction of glycine dehydrogenase activity and ICL activity in
aging or non-replicating cultures of M. tuberculosis (Murthy et al. 1973; Wayne
and Lin, 1982) suggested that glycine dehydrogenase might be responsible for
ICL-dependent, MLS-independent growth of M. smegmatis on acetate and fatty
acids. An obstacle to testing this hypothesis was the fact that the gene(s)
encoding glycine dehydrogenase activity had not been identified in mycobacteria.
The

M. tuberculosis genome contains at least three putative glycine

dehydrogenase (gcv) genes; the product of the most likely candidate gene, gcvB,
is thought to preferentially catalyze the decarboxyation of glycine rather than the
amination of glyoxylate (Cole et al., 1998; Wayne and Sohaskey, 2001).
Alanine dehydrogenase of M. smegmatis was reported to have preference
for the reductive amination of pyruvate to alanine; furthermore, it was induced in

M. smegmatis during dormancy, similarly to the glycine dehydrogenase activity in
the “Wayne model” of non-replicating persistence (Hutter and Dick, 1998). Usha

et al. (2002) purified the glycine dehydrogenase activity from M. smegmatis
grown under microaerobic conditions, and reported that the purified protein
could catalyze glyoxylate and pyruvate amination and L-alanine deamination.
They suggested that the alanine dehydrogenase (ALD) of M. smegmatis might be
responsible for metabolizing glyoxylate. Searches of the TIGR databases revealed
one ald gene in M. smegmatis, encoding a 371 aa protein. The ald gene was
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Figure 3.9. Southern blot to confirm the deletion of the ald gene in wild-type M.
smegmatis and in the ∆glcB strain. Selected restriction sites of the genomic region are

shown for the wild type (top) and mutant (bottom) alleles; the deletion introduced an
EcoRI site in the mutant strain. Genomic DNA was digested with PstI for the Southern
blot and the 800 bp region upstream of the gene was used as a probe. Expected bands:
2,664 bp for wild-type, 1,575 bp for ∆ald mutant. Strain 208-1-10 is the ∆glcB single
mutant; strain 213-2-9 is the ∆ald single mutant; strain 213-6-6 is the ∆glcB ∆ald double
mutant.
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deleted by creating an unmarked in-frame deletion that removed all but the first
6 and last 6 amino acids (Figure 3.9). The ald gene was deleted in wild type M.

smegmatis and in the ∆glcB strain. If ALD represented the ICL-dependent, MLSindependent activity, which enabled the ∆glcB mutant to grow on acetate and
glyoxylate, then the ∆glcB ∆ald double mutant should not grow on solid media
containing acetate or fatty acids as the sole carbon source. However, the ∆glcB
∆ald double mutant grew as well as the parental ∆glcB strain on media
contaioning acetate (Figure 3.10) or glyoxylate (not shown). It is thus clear that,
even if the M. smegmatis ALD could catalyze glyoxylate deamination, the product
of the ald gene is not essential for glyoxylate assimilation.
At the time the ∆ald and ∆glcB ∆ald mutants were generated in our lab, a
published report described the disruption of the ald gene in M. smegmatis (Feng

et al., 2002). In this study, the ald mutant had a defect in utilizing alanine as the
sole nitrogen source, and grew poorly under microaerobic conditions; however,
its glycine dehydrogenase activity remained at wild type levels, indicating that
another M. smegmatis enzyme was responsible for the reductive amination of
glyoxylate. Although the report by Feng et al. (2002) made it unnecessary to test
the glycine dehydrogenase activity in our ∆ald and ∆glcB ∆ald mutants, it
provided no indication as to which gene was encoding glycine dehydrogenase
activity and, more importantly, which other gene(s) encoded the ICL-dependent,
MLS-dependent pathway for growth on acetate and fatty acids.
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Figure 3.10. Alanine dehydrogenase (ALD) is not required for growth on acetate (or
glyoxylate or methylpalmitate, not shown). Thus, ALD does not seem to be required for
the assimilation glyoxylate, acetate, or fatty acids by M. smegmatis.
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3.4. Screen for C2 mutants in MLS-deficient M. smegmatis
To identify mutants that were defective in the putative ICL-dependent, MLSindependent pathway for growth on acetate and fatty acids, we created a library
of transposon mutants in the ∆glcB strain of M. smegmatis. Since the ∆glcB
mutant grew on acetate and fatty acids, albeit slowly, we screened for
transposon mutants that were completely unable to form colonies on agar plates
containing acetate and methylpalmitate as sole carbon sources. We then
transformed these Ace- Mep- mutants individually with a plasmid containing the

M. tuberculosis glcB gene, and screened for complementation of growth on
acetate and methylpalmitate. If we could restore a mutant’s ability to grow on
acetate and fatty acids by complementation with glcB, this would indicate that
the mutant was defective in the putative ICL-dependent, MLS-independent
pathway we were seeking (Figure 3.11).
We constructed a library of ~ 50,000 transposon mutants in the glcBdeficient strain by using the transposon donor phagemid φMycoMarT7 (Sassetti

et al., 2003), which was a generous gift from Dr. Eric Rubin (Harvard School of
Public Health). More than 4,000 transposon mutants were screened to identify
mutants that were capable of grow on glucose but not on acetate or
methylpalmitate. Of the 4,000 mutants screened, more than 50 were retested to
confirm their phenotypes; 24 bred true on retesting, and these were transformed
individually with a plasmid carrying a copy of the M. tuberculosis glcB gene. The
sites of transposon insertion in the 24 mutants were identified by subcloning the
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Figure 3.11. Top: Strategy to identify genes in M. smegmatis that are essential for
the function of the putative ICL-dependent, MLS-independent pathway for growth on
acetate and fatty acids as the sole carbon source. Figure provided by Dr. John
McKinney. Bottom: Southern blot of selected transposon mutants. Genomic DNA was
digested with BamHI or ApaLI (neither enzyme cuts within the phiMycoMarT7
transposon) and probed with the kanamycin resistance cassette from the transposon.
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transposon, along with flanking genomic DNA sequences, and sequencing the
genomic DNA by using a primer that hybridizes at the end of the kanamycin
resistance cassette internal to the transposon. Genomic DNA from the 24
mutants selected for complementation was subjected to sequencing and
Southern blotting to confirm that each mutant contained only one insertion
(Figure 3.11). Several of the transposon insertions were in the icl1 gene, which
was expected; all of the icl1 mutants failed to grow on both acetate and
methylpalmitate, and they were not complemented by glcB. Another transposon
insertion was in pckA encoding the gluconeogenic PEP carboxykinase; this
mutant also failed to grow on both acetate and palmitate, and was not
complemented by glcB. A large number of insertions mapped to the acs gene,
which encodes acetyl-CoA synthase; all of the acs mutants grew on
methylpalmitate but not on 0.1% acetate, the concentration of acetate used in
the plates for the screen. Several of the transposon insertions were in genes that
had no homologs in M. tuberculosis; several of the genes that did have clear
homologs in M. tuberculosis encoded hypothetical proteins of unknown function.
The identifies of the mutants generated in this screen and a screen to identify C2
transposon mutants in wild type M. smegmatis, are showin in Appendix A and B.
Importantly, 3 of the 24 mutants were unable to grow on acetate or
methylpalmitate, and were complemented by transformation with glcB (Figure
3.12). The first mutant, 2AH6 (Figure 3.12, F) grew rather poorly on glucose,
and did not grow at all on acetate or methylpalmitate. Addition of glcB improved

63

A
B
C
D
F
G
H
I
J
K
GLUCOSE

ACETATE

METHYLPALMITATE

Figure 3.12. Transposon mutants 2AH6 (F), 14AG2 (H), and 17BB5 (J) grow on
glucose (left) but cannot grow on acetate (middle) or methylpalmitate (right) as sole
carbon source; these mutants are complemented by glcB. Serial dilutions of late logphase cells were spotted on agar plates with 0.1% glucose or acetate, or 0.5% methylpalmitate. A, ∆glcB plus vector; B, ∆glcB plus M. tuberculosis glcB; C, wild-type plus
glcB; D, ∆icl1; F, mutant 2AHG plus vector; G, 2AHG plus glcB; H, mutant 14AG2 plus
vector; I, 14AG2 plus glcB; J, mutant 17BB5 plus vector; K, 17BB5 plus glcB.
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the growth of this mutant on all three carbon sources but the complementation
was partial (Figure 3.12, G). The second and third mutants, 14AG2 and 17BB5 (H
and J in Figure 3.12, respectively), grew as well as the ∆glcB strain on glucose
but did not grow on acetate or methylpalmitate unless they were complemented
with the glcB gene (I and K in Figure 3.12, respectively). As expected,
transformation of the M. tuberculosis glcB gene into the ∆glcB strain
complemented its moderate growth defect on solid media containing acetate or
methylpalmitate (A and B in Figure 3.12).
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3.5. Genomic characterization of the ∆glcB C2 transposon mutants
The identity of the three mutants of interest, 14AG2, 17BB5, and 2AH6, was
determined by sequencing the DNA immediately downstream of the transposon
insertion sites. The gene disrupted in mutant 14AG2 encoded a protein that had
homology to a group of acetolactate synthases in the M. tuberculosis genome; a
BLAST search against the non-redundant protein databases revealed that the
protein was homologous to glyoxylate carboligases in other species. Several kb
of DNA sequence upstream and downstream of the insertion site were
downloaded from TIGR’s databases and assembled with Vector NTI. Putative
ORFs were identified and the conceptual translation products were compared to
protein databases to deduce the identities of the genes in the region. Glyoxylate
carboligase appears to be in an operon along with genes encoding three
enzymes and a transcriptional regulator (Figure 3.13, A). The transposon
insertion in mutant 17BB5 mapped to a homolog of M. tuberculosis fadD1. The

M. smegmatis fadD1 gene lies upstream of an operon encoding ribosomal
proteins, and downstream of a gene cluster for threonine biosynthesis (Figure
3.13, B). The transposon insertion in 2AH6 mapped to an approximately 100 bp
intergenic region between two divergently transcribed genes predicted to encode
enzymes for the production of thiamine. As thiamine pyrophosphate is an
essential

cofactor

of

several

important

enzymes,

including

pyruvate

dehydrogenase, transketolase, acetolactate synthase, pyruvate decarboxylase,
and glyoxylate carboligase (Schorken and Sprenger, 1998), it seems unlikely that
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A.

B.

C.

Figure 3.13. Genomic structure of the (A) glyoxylate carboligase (GCL), (B) FadD1,
and (C) thiamine biosynthesis (ThiE/O) regions in M. smegmatis. Annotation of the

regions was done after sequencing the sites of transposon insertions in the mutants.
About 5-7 kb of sequence upstream and downstream of the insertion site were obtained
from TIGR’s unfinished genomes database, and BLAST searches were done with the
putative ORFs against the M. tuberculosis genome and against NCBI’s protein databases.
The names of the closest homologues are provided. Black line in C indicates the site of
transposon insertion in the intergenic region between thiE and thiO. The transposon
inserted in the coding regions of gcl and fadD1.
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2AH6 is a complete thiamine auxotroph, and we suspect that the mutant may be
impaired (but not null) for thiamine production by the insertion (Figure 3.13, C).
Upon annotating the genes surrounding gcl, it became apparent that gcl
forms a hypothetical operon with the preceding two genes. The stop codon of

hypI is 30 basepairs upstream of the translation start site of tsaR; the stop codon
of tsaR overlaps the start site of gcl. A 107 bp intergenic region separates the 3’
end of the gcl gene and the start site of gclR. The 27 bp palindromic sequence
ccactattcc acaccgc ggaatagtgg is located at nucleotides -27 to -53 upstream of
the gclR start codon; the 19 bp palindromic sequence ttttccg tattg cggaaaa is
found at nt -24 to -42 of hypI. Palindromic sequences upstream of genes can be
binding sites for the helix-turn-helix (HTH) transcriptional regulators of the
AraC/XylS family; a few representative members of this family are AraC, Crp,
GntR, IclR, LuxR and TetR (Callegos et al., 1997). It thus appears that the
hypothetical operon might be under the control of HTH regulators.
The gcl gene encodes for a putative protein of 599 amino acids. Searches
with the hypothetical M. smegmatis GCL sequence against the NCBI’s Conserved
Domains databases revealed that it contains two thiamine pyrophosphate (TPP)
binding sites in its N-terminal and central regions; it aligns closely with COG3960
(glyoxylate carboligase) from other species and has more limited similarity to
other TPP-requiring enzymes such as acetolactate synthase and pyruvate
carboxylase (Figure 3.14, A). The hypothetical product of tsaR is 305 aa in length
and has a hypothetical NAD+ binding domain in its N-terminus. TSAR appears to
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be a β-hydroxyacid dehydrogenase and is homologous to the well-characterized
enzymes β-hydroxyisobutyrate dehydrogenase, a requisite enzyme for valine
catabolism, and 6-phosphogluconate dehydrogenase, a NADP+-dependent
enzyme that plays a role in the pentose phosphate pathway by oxidizing 6phosphogluconate. The tartronate semialdehyde reductase of E. coli is a βhydroxyacid

dehydrogenase

with

homology

to

β-hydroxyisobutyrate

dehydrogenase and 6-phosphogluconate dehydrogenase (Njau et al., 2000).
Given the location of the M. smegmatis tsaR gene just upstream of gcl and the
homology between the hypothetical tsaR product and known TSAR proteins
(Figure 3.14, B), it is likely that tsaR encodes a tartronate semialdehyde
reductase.
The gene product just upstream of tsaR has homology to hydroxypyruvate
isomerases (COG3622). Makato and Misuno (1999) demonstrated that the E. coli

hyi gene, located immediately downstream of gcl and upstream of glxR encodes
a 258 aa hydroxypyruvate isomerase protein, which catalyzes the conversion of
tartronic semialdehyde to hydroxypyruvate. M. smegmatis hypI encodes a 278 aa
protein, most likely a hydroxypyruvate isomerase (Figure 3.14, C). Finally, the

gclR gene encodes a 255 aa peptide with an N-terminal HTH motif typical of the
IclR family of transcriptional regulators, and has significant overall homology to
IclR (Figure 3.14, D).
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Figure 3.14. Alignment of proteins in the gcl region with NCBI’s Conserved Domains
databases. GCL (A) belongs to the family of TPP (thiamine pyrophosphate)-dependent
enzymes. TSAR (B) is related to 3-hydroxyisobutyrate dehydrogenases and 6phosphogluconate dehydrogenases. HYPI (C) appears to be a hydroxypyruvate
isomerase, while the GclR protein (D) belongs to the IclR family of regulators.
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Figure 3.15. (A) tBLASTX of M. smegmatis GCL against NCBI’s databases. (B-D)
BLASTP of GCL (B), TSAR (C) and HYPI (D) proteins against M. tuberculosis genomes.
mmsB (C) is annotated as a 3-hydroxyisobutyrate dehydrogenase in the H37Rv genome.
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The gene names used here were assigned on the basis of results from
protein homology searches and comparison of the regions flanking the
transposon insertion in M. smegmatis to the gcl operon in the E. coli
chromosome (Cusa et al., 1999). In TIGR’s databases, these genes are assigned
MSMEG numbers 5454 (gclR), 5455 (gcl), 5456 (tsaR) and 5457 (hypI);
MSMEG5455 is annotated as glyoxylate carboligase, while the other three
proteins have not been assigned functions.
The protein sequences of the gcl locus were aligned against the genomes
of pathogenic mycobacteria on TIGR’s website (http://tigrblast.tigr.org/cmrblast/). The gcl gene is absent from the genomes of all sequenced pathogenic
species (M. avium, M. bovis, M. leprae, and M. tuberculosis). The ilv genes,
encoding acetolactate synthases, were the closest homologs of gcl in M.

tuberculosis (Figure 3.15, B). Similarly, the best tsaR matches were the M.
tuberculosis genes encoding β-hydroxyisobutyrate dehydrogenase and 6phosphogluconate dehydrogenase (Figure 3.15, C). No hits were obtained for
HYPI, suggesting that this protein is also missing in M. tuberculosis.
The gene disrupted in mutant 17BB5, on the other hand, had an obvious
homolog in M. tuberculosis (Figure 3.16). It is 62 percent identical to the FadD1
protein, with lesser homology to FadD17 and FadD6. Both FadD17 (Trivedi et al.,
2004) and FadD6 (Arora et al, 2005) were shown to synthesize the formation of
fatty acyl-CoA and not fatty acyl-AMP; FadD6 also showed broad specificity for
the length of its fatty acid substrates. These data indicate that FadD1 is probably
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A.

B.

Figure 3.16. tBLASTX of the M. smegmatis fadD1 locus against the H37Rv genome
(A), and the NCBI Conserved Domains databases (B). FADD1’s significant alignment
against COGs 0318, 0365, and 1022 suggests that it is a fatty acyl-CoA synthase.
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a fatty acyl-CoA ligase and does not play a role in polyketide synthesis.
The location of fadD1 in the genome of M. smegmatis suggests that it is
transcribed independently of surrounding genes (Figure 3.13, B). Interestingly, in

M. tuberculosis, the threonine biosynthesis (thr) gene cluster resides immediately
upstream of the ribosomal peptide genes. The order and orientation of the thr
and ribosomal synthesis genes are conserved in M. smegmatis, but fadD1 and
the putative transcriptional regulator gene AcrR are inserted in the middle.
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3.6. Metabolic characterization of the ∆gclB C2 mutants
The carbon requirements of the ∆glcB gcl and ∆glcB fadD1 mutants were more
fully characterized. The 2AH6 mutant, hypothesized to be partially defective for
synthesis of thiamine pyrophosphate, grew poorly on all carbon sources,
including glycerol and glucose, and complementation with glcB only partially
restored growth on all substrates (Figure 3.19). As thiamine pyrophosphate is a
cofactor necessary for the enzymatic activity of glyoxylate carboligase (Krakow et

al., 1961; Schorken and Sprenger, 1998) as well as other enzymes, 2AH6 was
not characterized as fully as the ∆glcB gcl and ∆glcB fadD1 mutants in
subsequent experiments.
The ∆glcB, ∆glcB gcl, and ∆glcB fadD1 mutants, as well as the
corresponding complemented strains carrying the M. tuberculosis glcB gene on a
plasmid, were assayed for growth in liquid minimal media containing glucose or
glyoxylate as carbon sources (Figure 3.17). All strains grew as well as wild type

M. smegmatis on glucose; however, only the wild type, ∆glcB, and
complemented ∆glcB strains grew at all on glyoxylate. This demonstrated that,
similarly to E. coli (Ornston and Ornston, 1969), the activity of malate synthase is
dispensable for growth on glyoxylate, and that glyoxylate carboligase is
absolutely required for assimilaiton of glyoxylate into the general metabolism of

M. smegmatis. Surprisingly, the ∆glcB fadD1 strain also failed to grow on
glyoxylate, regardless of whether malate synthase activity was present or not
(Figures 3.17, 3.18). Given that fadD1 appears to encode a fatty acyl-CoA ligase
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Figure 3.17. Growth of wild type M. smegmatis, mutant strains, and mutant strains
complemented with MTB glcB in M9 minimal media containing either 0.1% dextrose (top
panel) or 0.1% glyoxylate (bottom panel) as sole carbon sources. The growth studies
were done at least three times for each strain and carbon source; a representative
experiment is shown.
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Figure 3.18. Growth of M. smegmatis glyoxylate shunt mutants on glyoxylate as the
sole carbon source. Serial dilutions of early log-phase cultures of wild-type M. smegmatis

(A) and mutants were spotted on solid plates containing agar (top, square plates) or
agarose (bottom, round plates) as the solidifying agent, and 0.2% glyoxylate as the sole
carbon source. The ∆ald (D), ∆glcB (E, M) mutants, and the ∆glcB mutant
complemented with the MTB glcB gene (F, N) grew as well as wild-type bacteria,
indicating that ald and glcB are dispensable for growth on glyoxylate. Interestingly, the
∆icl1 (B) and ∆icl1 ∆icl2 (C) mutants appeared to have a slight growth defect on
glyoxylate plates, which was not the case with the ∆icl2 mutant (not shown). The
∆glcB gcl (I, O) and ∆glcB fadD1 (K, Q) strains did not grow on glyoxylate, even when
transformed with a plasmid containing the MTB glcB gene (J, P; L, R).
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(FACL), and FACLs have not been shown to play a role in the assimilation of
glyoxylate, it is unclear why the ∆glcB fadD1 strain is unable to grow on
glyoxylate media.
The mutant strains were further tested for their ability to grow on agar
plates or liquid minimal media supplemented with short-chain fatty acids as the
sole carbon sources. Agar plates containing C2, C4, C5, and C6 compounds were
checked for growth after one and three weeks of incubation at 37˚C. The ∆glcB
mutant had formed microscopic colonies on C2 and C6 after a week, and formed
large colonies on all plates after three weeks (Figure 3.19, left-most column).
The ∆glcB gcl mutant did not grow on C2, C4, or C6 fatty acids at any time;
restoration of malate synthase activity enabled it to assimilate these even-chain
fatty acids. Interestingly, the ∆glcB gcl strain did form colonies on valerate (C5)
after three weeks (Figure 3.19, left middle).
The ∆glcB fadD1 mutant behaved similarly to the ∆glcB gcl mutant, with a
few exceptions: it formed noticeable colonies on C5 sooner and it formed small
but discernable colonies on C4 and C6 after three weeks. Thus, the ∆glcB fadD1
mutation appeared to be slightly but perceptibly leaky on butyrate and hexanoic
acid. However, the ∆glcB fadD1 mutant, like the ∆glcB gcl strain, absolutely failed
to grow on C2 (acetate) unless complemented with glcB (Figure 3.19, right
middle column). Lastly, the 2AH6 mutant (∆glcB thi) eventually grew on all fatty
acids, regardless of whether it had malate synthase activity or not; in fact,
complementation enhanced its growth only on acetate, but rather minimally.
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Figure 3.19. Complementation of ∆glcB gcl and ∆gclB fadD1 mutants with the MTB
glcB gene (panels marked “+ tb glcB”) restores wild type growth on even-chain fatty
acids (acetate, C2; butyrate, C4; hexanoate, C6) as sole carbon sources. The ∆glcB thi
mutant can grow on media containing these substrates as sole carbon sources, albeit
poorly. The ∆glcB gcl mutant fails to grow on even-chain fatty acids even after 3 weeks,
while ∆gclB fadD1 forms small, but discernable, colonies on C4 (butyrate) and C6
(hexanoate) after 3 weeks. 2AH6 (∆glcB thi) grows slowly on all carbon sources,
including glucose (not shown); complementation with the MTB glcB gene enhances
growth of the ∆glcB thi mutant on acetate. “1” = one week of growth at 37˚C; “3” =
three weeks of growth at 37˚C.
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Figure 3.20. Growth of M. smegmatis in M9 liquid media containing 0.1% of the

indicated C2, C4, C5, C6, and C7 compounds as the sole carbon source. Strains:
(A,D,G,J,M) wild-type (squares), ∆glcB (empty triangles), and compl. ∆glcB (filled
triangles); (B,E,H,K,N) ∆glcB gcl (empty circles) and compl. ∆glcB gcl (filled circles);
(C,F,I,L,O) ∆glcB fadD1 (empty diamonds) and compl. ∆glcB fadD1 (filled diamonds).
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These results suggested that the ∆glcB gcl and ∆glcB fadD1 strains might
have different growth kinetics on fatty acids, and that they behave differently on
even- vs. odd-chain fatty acids. To address this issue, we grew these strains in
M9 minimal liquid media supplemented with C2-C7 fatty acids (Figure 3.20). In
M9 liquid media, the growth delay of the ∆glcB mutant was less pronounced than
on

solid

media,

but

nonetheless

significant

and

reproducible

(Figure

3.20A,D,G,J,M). The ∆glcB strain lagged behind wild-type bacteria when grown
on acetate (Figure 3.20A), which was not due to adaptation problems, as the lag
was not eliminated by pre-adaptation of ∆glcB cells to acetate (not shown). A
clear lag was also observed when the ∆glcB strain was cultured in C4 (Figure
3.20D), C6 (Figure 3.20J), or C7 (Figure 3.20M) media, but was very slight when
cells were grown in C5 medium (Figure 3.20G).
The ∆glcB gcl and ∆glcB fadD1 strains failed to grow in media containing
even-chain fatty acids of C2 (Figure 3.20B,C), C4 (Figure 3.20E,F), or C6 (Figure
3.20K,L) chain length. However, both strains were able to grow on media
containing C5/valerate (Figure 3.20H,I) and, to a lesser degree, C7/heptanoate
(Figure 3.20N,O). The ∆glcB fadD1 mutant consistently grew better than the
∆glcB gcl strain on C5 and C7 substrates; in fact, growth of the ∆glcB fadD1
(Figure 3.20I) and wild-type (Figure 3.20G) strains on C5/valerate was similar.
In media containing odd-chain fatty acids, the ∆glcB gcl and ∆glcB fadD1
strains grew better on C5/valerate than C7/heptanoate. A molecule of
C7/heptanoate is degraded, via β-oxidation, to yield two acetyl-CoA (C2) units
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Figure 3.21. Growth of M. smegmatis in liquid media containing acetate, propionate,
or a mixture of acetate and propionate as the sole carbon sources, as indicated. Strains:
(A,E,I,M) wild-type, ∆glcB, comp. ∆glcB; (B,F,J,N) ∆glcB gcl, comp. ∆glcB gcl;
(C,G,K,O) ∆glcB fadD1, comp. ∆glcB fadD1; (D,H,L,P) ∆icl1, ∆icl2, ∆icl1∆icl2. Note:
“comp” indicates that the corresponding mutant strain was complemented with MTB
glcB to restore malate synthase activity.
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and one propionyl-CoA (C3) unit, whereas β-oxidation of C5/valerate yields one
acetyl-CoA unit and one propionyl-CoA unit. We considered the possibility that, in
the absence of a functional glyoxylate shunt, the ∆glcB gcl and ∆glcB fadD1
strains might oxidize acetyl-CoA via the TCA cycle for energy generation and
assimilate propionyl-CoA via the methylcitrate cycle for anaplerosis. However,
our observations suggested that acetyl-CoA might exert a dominant inhibitory
effect in the absence of an intact glyoxylate shunt. We propose that catabolism
of longer odd-chain fatty acids would result in higher acetyl-CoA:propionyl-CoA
ratios in the cells, thereby increasing growth inhibition in proportion to chain
length. We tested this hypothesis by growing the ∆glcB gcl and ∆glcB fadD1
strains in M9 minimal media containing mixtures of propionate (C3) and acetate
(C2) in different ratios. We also tested the strains that lacked one, or both, of
the isocitrate lyase (icl) genes in these conditions. As shown in Figure 3.21D, the
∆icl1 and ∆icl1 ∆icl2 mutants, but not the ∆icl2 mutant, failed to grow on acetate,
as did the ∆glcB gcl (Figure 3.21B) and ∆glcB fadD1 (Figure 3.21C) strains. The
∆glcB mutant grew on 0.5 percent acetate (Figure 3.21A), but the lag was more
pronounced than when it was grown on 0.1 percent acetate (Figure 3.21E). As
expected, all strains grew well in media containing 0.1 percent propionate
(Figure 3.21E,F,G,H).
Interestingly, addition of acetate inhibited the ability of the ∆icl1 and
∆icl1 ∆icl2 mutants to grow on media containing propionate (Figure 3.21L,P).
There are several possible explanations for this phenomenon: a) acetate is toxic
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to cells unless they can assimilate it via the glyoxylate cycle; b) high
concentrations of acetate may inhibit some enzymes, or the transcription of
some genes, which are involved in propionyl-CoA metabolism; c) ACKA converts
acetate to acetyl-phosphate, which is a global regulator of gene expression in E.

coli (Wolfe, 2005), and acetyl-phosphate-mediated changes in gene expression
could be growth-inhibitory in mycobacteria; d) acetate is converted to acetylCoA, which, at high levels, can be inhibitory to a number of important enzymes.
Also of note is the fact that the presence of a functional icl2 gene can partially
compensate for the loss of icl1 at moderate concentrations of acetate in the
media (Figure 3.21L) but not at high acetate concentrations (Figure 3.21P). It
appears that icl1 can effectively buffer loss of icl2, inasmuch as deletion of icl2
alone had no effect on bacterial growth on any substrates or substrate mixtures
examined (Figure 3.21D,H,L,P).
The ∆glcB mutant grew well in mixtures of 0.5 percent acetate and 0.1
percent propionate (Figure 3.21I), suggesting that GCL can effectively
metabolize the glyoxylate that is produced by isocitrate lyase at this acetate
concentration. However, in mixtures of 1.0 percent acetate and 0.1 percent
propionate (Figure 3.21M), growth of the ∆glcB strain was paritally inhibited,
perhapse due to accumulation of glyoxylate or acetyl-CoA under these
conditions.
The ∆glcB gcl mutant was unable to grow on 0.1 percent propionate in
the presence of 0.5 percent (Figure 3.21J) or 1.0 percent (Figure 3.21N) acetate,
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despite being capable of normal growth on media containing 0.1 percent
propionate alone (Figure 3.21F). We hypothesize that isocitrate lyase converts
acetate to glyoxylate, which accumulates to inhibitory levels in the absence of
GlcB and GCL. Consistent with this hypothesis, glyoxylate-mediated growth
inhibition has been demonstrated in a malate synthase mutant of Rhodococcus

fascians (Vereecke et al., 2002).
Interestingly, the ∆glcB fadD1 mutant is capable of growth on propionate
alone (Figure 3.21G) as well as mixtures of acetate and propionate (Figure
3.21K,O), despite being completely unable to utilize acetate alone (Figure
3.21C). Since either malate synthase (Figure 3.21J,N) or glyoxylate carboligase
(Figure 3.21I,M) appears to be sufficient for growth in media containing
acetate/propionate mixtures, the ∆glcB fadD1 mutant may induce glyoxylate
carboligase activity when provided with propionate plus acetate, or with oddchain fatty acids, as the carbon source. We propose a model in which FadD1 is
required to upregulate (probably indirectly) the expression or activity of
glyoxylate carboligase during growth on acetate (or even-chain fatty acids) as
the sole substrate; this requirement would be partially bypassed during growth
on mixtures of acetate and propionate (or odd-chain fatty acids), via an unknown
mechanism.
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3.7. FadD1-mediated regulation of the gcl operon
To examine the possible regulation of the gcl operon by FadD1, cell-free extracts
were prepared from wild-type bacteria grown on glucose, valerate (C5), or a 1:1
mixture of acetate (C2) and propionate (C3), and the activity of TSAR (tartronate
semialdehyde reductase) was measured spectrophotometrically in a coupled
enzyme assay. Each molecule of the reduced tartronic semilaldehyde oxidizes a
molecule of NADH to NAD+, so the conversion of tartronic semialdehyde to dglycerate can be quantified by measuring the disappearance of NADH at 340 nm
(Hansen and Hayashi, 1962). Tartronic semialdehyde was generated in situ from
glyoxylate by GCL upon the addition of MgCl2 and TPP (see Schematic in Figure
3.22A)
Cell-free extracts of wild-type M. smegmatis grown on glucose contained
no appreciable GCL-TSAR activity (Figure 3.22B, filled diamonds), but activity
was readily detected in extracts from bacteria grown in media containing
valerate (Figure 3.22B, crosses) or acetate+propionate mixtures (Figure 3.22B,
filled triangles). Production of tartronic semialdehyde was apparently dependent
on glyoxylate carboligase activity, because reactions in which thiamine
pyrophosphate (TPP) and MgCl2 were omitted were negative for NADH oxidation
(Figure 3.22B, empty squares). Extracts from ∆glcB fadD1 bacteria grown in
valerate or acetate+propionate mixtures contained substantially reduced GCLTSAR activity (Figure 3.22B, righthand panel), as compared to extracts from
wild-type bacteria grown under the same conditions (Figure 3.22B, lefthand
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Figure 3.22. A functional copy of fadD1 is required for the full induction of GCL-TSAR
activity in M. smegmatis. (A) Schematic of the coupled GCL-TSAR assay in cell-free
extracts. The reaction mixture contains glyoxylate as the substrate; upon the addition of
TPP and MgCl2, two molecules of glyoxylate are condensed to one tartronic
semialdehyde (by GCL), which is reduced to glycerate with concomitant oxidation of
NADH to NAD+ (by TSAR). NADH oxidation is measured spectrophotometrically at 340
nm. (B) In wild-type M. smegmatis (left panel), GCL-TSAR activity was not detected in
cultures grown on glucose (glu) or when TPP/MgCl2 were not added to the reaction mix
(- tpp). GCL-TSAR activity was strongly induced in cultures grown on acetate/propionate
(a/p) or valerate (val). Extracts from ∆glcB fadD1 bacteria grown on acetate/propionate
or valerate contained reduced, but still detectable, GCL-TSAR activity (right panel),
suggesting that a FadD1-independent mechanism for induction of GCL-TSAR activity
might exist in M. smegmatis.
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panel). Nonetheless, TSAR activity was still detectable in extracts from the
∆glcB fadD1 bacteria grown in valerate or in acetate+propionate, suggesting
that a second, FadD1-independent mechanism for regulation of the gcl operon
might exist in M. smegmatis. This mechanism might involve activation by a C3
unit, which could be generated from metabolism of propionate or odd-chain fatty
acids.
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3.8. In-frame deletions of gcl and fadD1 in M. smegmatis
The experiments described so far were carried out in strains of M. smegmatis
that harbored in-frame deletions in glcB and ald, as well as tranposon insertions
in glyoxylate carboligase (gcl), fatty acyl-CoA ligase 1 (fadD1), and the intergenic
space between thiO and thiE. To rule out the possibility of polar effects of the
transposon insertions on genes downstream of the transposon insertion sites, we
generated strains that carried unmarked, in-frame deletions in either gcl or

fadD1 on both the wild type background and the ∆glcB background. These four
strains (∆gcl, ∆fadD1, ∆glcB∆gcl, and ∆glcB∆fadD1) were then plated on agar
plates containing glucose, glyoxylate, or various chain-length fatty acids (from
C2/acetate to C5/valerate) as the sole carbon substrates.
None of these four strains could grow on glyoxylate plates, confirming
that, in M. smegmatis, both GCL and FadD1 activities are necessary for utilization
of glyoxylate as the sole carbon source (not shown). The single ∆gcl and ∆fadD1
mutants grew as well as wild-type bacteria on all other carbon sources, including
acetate and the short chain fatty acids butyrate (C4) and valerate (C5),
confirming that malate synthase is the dominant anaplerotic pathway for
assimilation of the glyoxylate produced by isocitrate synthase when M.

smegmatis grows on acetate or fatty acids. Finally, similarly to what we observed
with the transposon-induced double mutants, the ∆glcB∆gcl and ∆glcB∆fadD1
strains could not grow on acetate or butyrate as the sole carbon sources, but
could form colonies on valerate after prolonged incubation (not shown). The
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phenotypes of the ∆glcB gcl and ∆glcB fadD1 transposon mutants were thus
solely due to loss of GCL and FadD1 activities.
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CHAPTER 4
Understanding Glyoxylate Metabolism In Mycobacteria
4.1. The role of malate synthase in pathogenic mycobacteria
Muñoz-Elías and McKinney (2005) reported that the two isocitrate lyases (ICL) of

M. tuberculosis are jointly required for virulence in the lungs of infected mice.
They also demonstrated that the two enzymes were necessary for bacterial
growth on acetate (C2), butyrate (C4), laureate (C12) and palmitate (C16). Thus,
it appears that, in M. tuberculosis, the ability to assimilate fatty acids (or at least
even-chain fatty acids) through the glyoxylate shunt may correlate with the
ability of the tubercle bacillus to grow and persist in vivo.
This correlation between the ability to carry out β-oxidation in the lungs of
infected hosts and the ability to cause disease is consistent with evidence
presented by Segal and Bloch (1956), Kanai and Kondo (1974) and Bharadwaj et

al., (1987), which suggested that lipid, rather than carbohydrate, catabolism was
of crucial importance to the in vivo survival of pathogenic mycobacteria.
Similarly, Raynaud et al.’s (2002) report that exported phospholipase C isoforms
may be required for virulence lends further support to the idea that β-oxidation
may be important in vivo. The results presented by Muñoz-Elías and McKinney
(2005) suggest that novel drugs that can target both ICLs of mycobacteria could
be effective new therapeutics for treating active mycobacterial infections.
However, despite the unambiguous importance of ICLs in mycobacterial
pathogenesis, it is not clear if the other enzyme of the glyoxylate shunt, malate
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synthase (MLS), is equally important for M. tuberculosis virulence. So far, for
reason unknown, it has not been possible to isoalte a strain of M. tuberculosis
harboring a null mutation in the glcB gene (Muñoz-Elías, 2005, Ph.D. thesis). It is
possible that MLS activity is essential in pathogenic mycobacteria, and that a
∆glcB strain will never be obtained. In that case, MLS could still be a viable
target for novel drug development. The potential essentiality of glcB needs to be
demonstrated experimentally, however; experiments to that end are ongoing in
our laboratory.
It is also plausible that the importance of ICL1/ICL2 in vivo is due to their
participation in a pathway that does not involve MLS. One such pathway is the
methylcitrate cycle, which appears to be the dominant pathway for metabolism
of propionyl-CoA in bacteria (Figure 4.1; Textor et al., 1997; Horswill and
Escalante-Semerena, 1999; Claes et al., 2002). The putative involvement of M.

tuberculosis ICL, but not MLS, in the methylcitrate cycle came from the
unexpected observation that ICL1/ICL2 were jointly required for in vitro growth
of M. tuberculosis on propionate, and from the fact that M. tuberculosis lacks a

prpB homolog encoding methylisocitrate lyase (Muñoz-Elías and McKinney, 2005;
Muñoz-Elías and McKinney, 2006). Recently, however, Muñoz-Elías et al. (2006)
reported that, although ICL1/ICL2 in fact do have have methylisocitrate lyase
activity and participate in the methylcitrate cycle, the methylcitrate cycle (and
perhaps, by extension, propionate metabolism) is not important for the ability of

M. tuberculosis to establish and maintain infection in the lungs of mice. Thus, the
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Figure 4.1. Glyoxylate cycle (GC), top; methylcitrate cycle (MCC), bottom. Diagrams
were modified from Clark and Cronan (1996).
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importance of ICL1/ICL2 in vivo seems to be restricted to, or in addition to, their
role in the glyoxylate cycle. A scenario could be envisaged, however, in which
despite the essentiality of ICLs in vivo, it is the glycine dehydrogenase activity
reported by Wayne and Lin (1982), and not the MLS activity of glcB, that would
be critical for the ability of the tubercle bacillus to survive and persist in host
tissues. Thus, Boshoff and Barry (2005) propose that ICLs may be crucial as
members of a pathway to regenerate reducing equivalents when no external
electron acceptors (such as oxygen) are available, rather than as anaplerotic /
gluconeogenic activities. They suggest that the importance of glyoxylate
generation by ICL might lie in the fact that glyoxylate reduction by glycine
dehydrogenase

would

reoxidize

one

molecule

of

NADH.

Under

these

circumstances, MLS activity might not be essential.
Such questions will not be answered conclusively until strains lacking MLS
or glycine dehydrogenase activities are generated and tested for in vivo survival
and virulence. As discussed already, creating a strain of M. tuberculosis lacking
glycine dehydrogenase is could be problematic since it is still not known exactly
which gene encodes this activity. The most likely candidate, gcvB, might encode
a protein that selectively decarboxylates glycine (Cole et al., 1998; Wayne and
Sohaskey, 2001). Another potential confounder for genetic studies is that gcvB
might be an essential gene (Sassetti et al., 2003). Therefore, generating a strain
of M. tuberculosis lacking MLS activity, and then evaluating its properties in vivo,
could be the only way to ascertain, unambiguously, the reason why ICL activity
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is essential in vivo: for generating reducing equivalents, or for achieving
anaplerosis (and initiating gluconeogenesis) during growth on fatty acids as the
major available carbon source in the lungs of infected mammals.
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4.2. The role of malate synthase in non-pathogenic M. smegmatis
We report here that malate synthase (MLS) activity is non-essential in M.

smegmatis. The ICL (icl1, icl2) and MLS (glcB) genes can be deleted in M.
smegmatis without affecting growth on glucose, glycerol, or propionate as the
sole carbon source. While icl1 is essential for M. smegmatis growth on acetate
and even-chain fatty acids, glcB is dispensable for growth on these substrates,
although it is required for optimal growth under these conditions. The icl2 gene
appears to be completely dispensable for growth on all substrates tested.
The ∆glcB strain has a significant phenotype on acetate and even-chain
fatty acids. Compared to wild-type M. smegmatis, the ∆glcB mutant grows more
slowly on solid media containing acetate or even-chain fatty acids as the sole
carbon source, and it exhibits a reproducible growth lag in M9 liquid media
conatinaing acetate (C2), hexanoate (C6), and, to a lesser extent, butyrate (C4)
(Figure 3.20). Furthermore, increased concentrations of acetate exacerbate the
growth defect of the ∆glcB strain, even when a metabolizable carbon source
such as propionate is provided (Figure 3.21).
An intact copy of glcB clearly improves the ability of M. smegmatis to grow
on acetate and fatty acids; indeed, MLS is the dominant anaplerotic enzyme for
glyoxylate assimilation during growth on these substrates. Expression of MLS
activity completely masks the loss of glyoxylate carboligase activity on all carbon
substrates tested, with the exception of glyoxylate. ICL-MLS thus represents the
main anaplerotic pathway on acetate or fatty acid substrates in M. smegmatis.
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4.3. The role of glyoxylate carboligase in M. smegmatis
This thesis provides the first idenfication of mycobacterial genes encoding an
operon for the utilization of glyoxylate as the sole carbon source. Glyoxylate
carboligase activity was first reported in E. coli (Krakow and Barkulis, 1956) and
in Pseudomonas sp. (Kornberg and Sadler, 1960). This “d-glycerate pathway”
comprises

the

enzymes

glyoxylate

carboligase,

tartronate

semialdehyde

reductase, and glycerate kinase, which convert two molecules of glyoxylate (C2)
into one molecule of d-glycerate (C3) and then 3-phosphoglycerate (Ornston and
Ornston, 1969; see Figure 2.10). The significance of this pathway to the
physiology of M. smegmatis is that it enables the organism to grow on poor
carbon substrates like glyoxylate. M. smegmatis also appears to have at least
two homologs of E. coli glycolate oxidases, which can convert glycolate to
glyoxylate, so M. smegmatis might also be capable of growth on glycolate.
Unlike in E. coli, the M. smegmatis gcl operon represents a second
pathway, besides MLS, for assimilation of the glyoxylate that is produced by ICL
during growth on acetate or fatty acids. In this context, the d-glycerate pathway
can perform an anaplerotic role similar to the glyoxylate shunt. The anaplerotic
role of glyoxylate carboligase during growth on acetate or fatty acids would
normally be masked by the presence of MLS. The reaction catalyzed by MLS
produces malate, a four-carbon molecule, from two C2 units; glyoxylate
carboligase produces a three-carbon molecule from two C2 units, so this reaction
is not as efficient at assimilating carbon, unless glyoxylate is the sole substrate.
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The experiments performed here allow us to revisit the work of Ornston
and Ornston (1969) on the fate of the 3-phosphoglycerate molecule produced by
the d-glycerate pathway. Kornberg and Sadler (1960) had proposed the
existence of a dicarboxylic acid cycle, in which MLS activity was required for the
oxidation of glyoxylate by E. coli. Hansen and Hayashi (1962) argued that
glyoxylate was eventually oxidized by the tricarboxylic acid cycle, obviating the
need for MLS and the glyoxylate shunt (Figure 4.2). Our experiments with M.

smegmatis argue that glyoxylate is indeed oxidized through the TCA cycle, as the
∆glcB mutant grows on glyoxylate as well as wild-type bacteria. Therefore, the
dicarboxylic acid cycle, although it may operate in M. smegmatis, is apparently
not essential for the oxidation of glyoxylate. This conclusion was also reached by
Ornston and Ornston (1969), when they obtained E. coli mutants lacking malate
synthase G activity.
However, the TCA cycle oxidation model of Ornston and Ornston (Figure
4.2B) needs to be updated, as it implies the existence of an anaplerotic step for
the formation of malate, which would be catalyzed by malate synthase A. While
that may be the case in E. coli, where two malate synthases exist, it cannot be
the case in M. smegmatis, as deletion of the sole MLS gene (glcB) still allows
growth on glyoxylate. Most likely, 3-phosphoglycerate is converted to PEP or
pyruvate, followed by conversion of PEP to oxaloacetate by PEP carboxylase, or
by conversion of pyruvate to oxaloacetate by pyruvate carboxylase (Figure 4.3).

M. smegmatis has one ppc and two pca genes in its genome.
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A.

B.

Figure 4.2. Pathways for oxidation of glyoxylate in E. coli. Solid lines stand for
oxidative reactions, dashed lines represent anaplerotic reactions. (A) According to the
dicarboxylic acid cycle mechanism (Kornberg and Sadler, 1960), malate synthase is an
oxidative enzyme. (B) In the tricarboxylic acid cycle diagram, glyoxylate carboligase is
an oxidative enzyme, and anaplerosis is achieved by malate synthase A (Hansen and
Hayashi, 1962). Drawings were reproduced from Ornston and Ornston (1969).
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4.4. The Role of FadD1 in M. smegmatis
The deletion of both the glcB and gcl genes resulted in a mutant that behaves
exactly like the ∆icl1 ∆icl2 mutant: it cannot grow on acetate or even-chain fatty
acids. It thus appears that the d-glycerate pathway is the ICL-dependent, MLSindependent anaplerotic pathway that we set out to discover. However,
disruption of fadD1 resulted in a phenotype very similar to that obtained by
disruption of gcl, inasmuch as the ∆glcB gcl and ∆glcB fadD1 mutants could not
grow on acetate or even-chain fatty acids. More importantly, the double mutants
could not use glyoxylate as the sole carbon source, while the ∆glcB single mutant
could. These results suggest that FadD1 might activate the expression of the gcl
operon. The assays shown in Figure 3.22 suggests that the activity of FadD1 is
partially required to induce the gcl operon during growth on valerate or
acetate/propionate, indicating that another activator of the gcl operon may exist.
FadD1 is most likely a fatty acyl-CoA ligase, and fatty acyl-CoAs have been
shown to inactivate the regulator FadR in E. coli (Black and DiRusso, 2003).
When FadR binds the fatty acyl-CoA molecule, it dissociates from the operators
in its target promoters and allows for transcription of the downstream genes. It
is tempting to suggest a similar mechanism for FadD1. However, mycobacteria
do not have an obvious FadR homolog, and little is known about how gene
regulation works in mycobacteria. The hypothetical product of the GclR gene has
homology to the IclR transcription factor in E. coli. It is known that IclR
represses the aceBA genes in E. coli, and this repression is relieved by the
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binding of PEP to IclR (Cortay et al., 1991). FadR also activates expression of iclR
(Gui et al, 1996).
It is currently unknown whether a similar transcriptional control
mechanism exists in M. smegmatis. The gcl operon has two palindromic sites,
which could serve as binding sites for transcriptional activators/repressors: one
upstream of hypI, and one upstream of gclR. GclR itself may be involved in the
regulation of the expression of the gcl operon, but the mode of regulation needs
to be determined experimentally. Since little is known about the modulation of
gene expression in mycobacteria, regulation of the gcl operon could involve a
novel mechanism.
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4.5. The malate synthase of pathogenic mycobacteria
The malate synthase activity in M. smegmatis is dispensable for growth on C2
units because of the presence of the d-glycerate pathway. As it was pointed out,
however, the genes of the d-glycerate pathway are not found in any pathogenic

Mycobacterium species. The closest homologs of glyoxylate carboligase that are
found in the M. tuberculosis genome are the acetolactate synthases. In E. coli, it
was shown that acetolactate synthase could catalyze condensation of two
glyoxylate molecules to form tartronate semialdehyde; however, this reaction
was so inefficient that it would be probably be physiologically meaningless
(Chang et al., 2003). M. smegmatis possesses a number of genes encoding
acetolactate synthase homologs, yet these genes apparently cannot compensate
for the loss of glyoxylate carboligase activity.
The ∆glcB and ∆glcB gcl strains of M. smegmatis complemented with a
copy of the M. tuberculosis glcB gene could be useful tools for testing potential
inhibitors of the M. tuberculosis MLS. Should MLS be essential for survival of M.

tuberculosis in vivo, as has been shown for ICL1/ICL2, MLS inhibitors could serve
as leads for the development of novel drugs for treatment of tuberculosis.
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Figure 4.3. Glyoxylate assimilation in M. smegmatis. Abbreviations: ICL, isocitrate
lyase; MLS, malate synthase; GCL, glyoxylate carboligase; TSAR, tartronic semialdehyde
reductase; GLXK, glycerate kinase.
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CHAPTER 5
Materials and Methods
5.1. Bacterial strains and media

M. smegmatis mc2155 was stored at -80C in 15% glycerol.
Bacteria were grown at 37˚C; in Middlebrook 7H9 broth (DIFCO) with 10% ADS
(DIFCO), 0.5% glycerol, and 0.05% Tween-80; on Middlebrook 7H10 agar
(DIFCO) containing 10% ADS and 0.5% glycerol.
Antibiotics: hygromycin (50 µg/ ml), kanamycin (25 µg /ml) (Sigma)
M9 minimal media: M9 salts (DIFCO), 0.1 mM CaCl2, 2mM MgSO4; agar was
added at 15 grams per liter. Carbon substrates (from Sigma) were added at
(w/v) 0.1%, 0.2%, or 0.5% (for methylpalmitate).

5.2. Growth curves in minimal media/growth on agar plates

M. smegmatis mc2155 and mutant strains were grown in Middlebrook 7H9 broth
to OD600 of 1.0, then diluted to final OD600 in M9 media + 0.1% glucose, grown
again to OD600 of 1.0, then diluted in M9 media + 0.1% or 0.2% of the indicated
carbon sources. For plating on M9 solid media, cells grown in M9 media plus
0.1% dextrose were serially diluted in PBS + 0.1% Tween 80, plated on solid
media, and incubated at 37˚C for the indicated times

5.3. Construction of transposon libraries
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The φMicoMarT7 transposon donor phagemid was provided by Dr. Eric Rubin
(Harvard School of Public Health). M. smegmatis mc2155 was grown to OD600 of
1.0 in 7H9 media, washed twice with MP buffer (50 mM Tris, pH 7.5, 150 mM
NaCl, 10 mM MgSO4, 2 mM CaCl2) and resuspended in 1/10th original volume in
MP buffer. 1010 PFU (plaque-forming units) of phage per ml of original culture
was added for 3 hrs at 37˚C. Infected cells were plated on 7H10 agar with 10%
ADS, 0.5% glycerol, 0.5% glucose, and 25 µg/ml kanamycin. After 3 days,
distinct colonies were individually picked with sterilized toothpicks in 96 well
plates containing 7H9 plus 0.5% glucose for 2 days, then spotted with a multichannel pippetor on M9 agar plates containing 0.1% dextrose, 0.1% acetate, or
0.5% methylpalmitate as sole carbon source. Plates were incubated at 37˚C for
5 days. Original 96 well master plates were stored at –80˚C. Mutants with the
desired phenotypes were selected, grown in 7H9 media, and then tested for
growth in M9 liquid or M9 agar.

5.4. Generation of deletion mutants
5.4.1. Deletion of glcB gene
A 3.8 kb NotI-XmaI genomic fragment containing the M. smegmatis glcB gene
was obtained from a cosmid and subcloned in pBSKS (pBluescript) digested with
NotI and XmaI. The new construct was cut with MscI and the 1.9 kb (smaller)
fragment was removed. The larger fragment containing upstream and
downstream regions was purified and re-ligated. The truncated gene was cut out
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with NotI and XmaI, subcloned into p2NIL digested with NotI and XmaI, then
ligated into pGOAL19 as described (Parish and Stoker, 2000) to give the glcB
knockout vector. p2NIL and pGOAL19 have been described previously (Parish
and Stoker, 2000); they were a generous gift from Dr. Tanya Parish. The glcB
knockout plasmid was electroporated in M. smegmatis, and mutant strains were
selected as described in Figure 3.0. The glcB complementing integrative vector
was pEM186, provided by Ernesto Muñoz-Elías; it contains a 10,107 base pair
genomic region from H37Rv including the full-length glcB gene. In particular, it
contains nucleotides 2,081,482 to 2,091,588 of the H37Rv genome, as it is
annotated on Tuberculist (http://genolist.pasteur.fr/TubercuList/). The cosmid
contains genes rv1836c, glcB (rv1837c), rv1838c, rv1839c, and rv1840c. It was
electroporated into the ∆glcB strain and into individual ∆glcB transposon mutants
and transformants were selected on 7H10 agar containing hygromycin.

5.4.2. Deletion of icl1 gene
A 2.3kb fragment containing the entire icl1 gene of M. smegmatis was amplified
by PCR from genomic DNA using primers (the XhoI binding site is underlined):
smicl1upxhoI: 5-CTCGAGCTTCGACCACATGAACAACG-3;
smicl1dnxhoI: 5-CTCGAGGATCTTCATGATCGGGATGC-3.
The PCR product was subcloned into pCR2.1 and sequenced. A 2.3kb EcoRI
fragment containing the PCR product was subcloned into EcoRI-digested pBSKS
(pBluescript) then digested with SfoI to remove an 855 bp fragment internal to
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the icl1 gene (the deletion removes 285 amino acids from the ICL protein,
including the catalytic site, and results in an in-frame deletion in the ORF). The
other (5.4kb) SfoI fragment was re-ligated, and then digested with XhoI to
excise the 1.5kb band containing the truncated icl1 gene. This 1.5kb fragment
was subcloned into XhoI-digested pJG1100 vector (a gift from Dr. James Gomez)
to create the icl1 knockout plasmid. It was electroporated in wild type M.

smegmatis and the ∆icl2 strain and mutants were isolated by the two-step
counterselection method described in Figure 3.0.

5.4.3. Deletion of the icl2 gene
The icl2 gene was deleted by Ernesto Muñoz-Elías. For disruption of icl2, a 3.9kb
AgeI fragment from cosmid pEM353 (the M. smegmatis cosmid genomic library
was a gift of B. Subramanian, AstraZeneca Research Foundation) carrying icl2
was cloned into pSL301 to generate pEM701, which was digested with EcoRV to
obtain a 3.5kb fragment carrying icl2, which was then cloned into the PmeI site
of pJG1001 to generate pEM902. pEM902 was BstEII-digested to remove a 660bp fragment, which generated an unmarked in-frame deletion after re-ligation
into pEM903. The deletion encompasses amino acids 307-526 of the icl2 ORF.
pEM903 was electroporated into wild-type M. smegmatis and mutants were
isolated by the two-step counter-selection method described in Figure 3.0.

5.4.4. Deletion of the ald gene
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The upstream and downstream regions of ald were PCR amplified using primers:
Ald-up-F: TTAATTAAGAGGGCTCGGCCATCTCG (underlined is the PacI site)
Ald-up-R: GAATTCCGGGATTCCGACGAGCAT (underlined is the EcoRI site)
Ald-dn-F; GAATTCGCACAGTTCCTGGCGTAA (underlined is the EcoRI site)
Ald-dn-R: GGCCGGCCGTCCTTGAGGACGACGGT (underlined is the AscI site)
The upstream and downstream regions (about 800 bp each) were PCR amplified
and subcloned in pCR2.1 and sequenced. Correct clones were digested with PacI
- EcoRI (Ald-Up) and AscI - EcoRI (Ald-Dn) and subcloned (3 fragment ligation)
in PacI-AscI-digested pJG1004 to create the ald knockout plasmid. pJG1004, an
earlier version of pJD1100, was a gift from Dr. James Gomez. The ald KO
plasmid was electroporated into M. smegmatis and ald was deleted by the twostep counter-selection method described in Figure 3.0.

5.4.5. Deletion of the gcl gene
The upstream and downstream regions of gcl were PCR amplified using primers:
Gcl-up-L1: TTAATTAACCAGCTGATCGTGGCGGG (PacI site underlined)
Gcl-up-R1: CCTAGGCATGCGGGTCATGGCCGC (AvrII site underlined)
Gcl-dn-L1: CCTAGGGCGCTGTTCGATTAGTGA (AvrII site underlined)
Gcl-dn-R1: GGCGCGCCAGATCGCGGACGTCGTTG (AscI site underlined)
The upstream PCR product (up primers) was ~400 basepairs, while the
downstream PCR product (dn primers) was ~600 basebairs. PCR products were
subcloned in pCR2.1 using the TopoTA kit (Invitrogen) and several clones were
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sequenced. Fragments with the correct sequence were subcloned in pJG1100 in
a stepwise fashion: first the upstream region was excised with PacI-AvrII, and
subcloned into PacI-AvrII-digested pJG1100; then the downstream region was
excised with AscI-AvrII and subcloned into AscI-AvrII-digested vector. ∆gcl and
∆glcB∆gcl mutants were isolated by the two-step counter-selection method
described in Figure 3.0.

5.4.6. Deletion of the fadD1 gene
The upstream and downstream regions of fadD1 were PCR amplified using
primers:
FadD1-up-L1: TTAATTAAACTCCTCGGGTTCGTCGA (PacI site underlined)
FadD1-up-R1: CCTAGGCTGCAGCGTATCGGCCAT (AvrII site underlined)
FadD1-dn-L1: CCTAGGGCGCCAGGAATATCCCCT (AvrII site underlined)
FadD1-dn-R1: GGCGCGCCGAGCTCGCGGGCCGCCTC (AscI site underlined)
The upstream region PCR fragment (~500 basepairs) and downstream PCR
fragment (~700 basepairs) were subcloned into pCR2.1 using the TopoTA kit
(Invitrogen) and sequenced. Correct clones were subcloned into pJG1100 the
same way the gcl knockout plasmid was generated, and ∆fadD1 mutants were
isolated using the two-step counter-selection method described in Figure 3.0.

5.5. DNA manipulation
5.5.1. Identification of transposon mutants
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M. smegmatis genomic DNA was isolated as described (Muñoz-Elías et al., 2005)
and digested with BamHI or ApaLI. One half of the digested DNA was used for
Southern blotting, the other was ligated with T4 ligase (NEB) overnight and
transform in Pir1 competent E. coli cells (Invitrogen). Kanamycin-resistant
colonies were isolated, and plasmid DNA was isolated and sequenced using the
primer cttctgagcgggactctgggg, which hybridizes near one end of the
φMycoMarT7 transposon.

5.5.2. Southern blots
5 micrograms of genomic DNA was digested with the indicated restriction
enzymes, separated on 1% TBE gels, transferred to Hybond N membrane
(Amersham), and probed with

32

P-labeled DNA using the random primer labeling

kit (Boehringer Mannheim) and hybridized from 2 hours to overnight. The
hybridized membrane was sequentially washed with 2X SSC, 0.1% SDS and 0.1X
SSC, and 0.1% SDS before exposing the membrane to autoradiography

5.6. Enzyme assays
5.6.1. Malate synthase assay
Cells were harvested, washed three times with PBST (PBS plus 0.05% Tween
80), and resuspended in Tricine buffer (20 mM Tricine pH 7.5, 5 mM MgCl2, 1
mM EDTA) supplemented with protease inhibitors (Sigma). The cells were
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disrupted by bead-beating and the cell-free extract was clarified by centrifugation
in a tabletop centrifuge for 30 min at 14,000 rpm at 4˚C.
For MLS assays, a protocol modified from Smith et al. (2003) was used. In
1 ml final volume, 20 mM Tricine-HCl pH 7.5, containing 5 mM MgCl2, 0.8 mM
EDTA, 0.2 mM glyoxylate, and 0.2 mM acetyl-CoA were mixed with 50 microliters
of protein extract stored in Tricine-HCl pH 7.5, 5 mM MgCl2, and 0.8 mM EDTA
buffer, and the reaction was incubated at room temperature for 30 min. The
reaction was stopped by adding DTNB (Sigma) to a final concentration of 2 mM
in Tris-HCl pH 8.0. The amount of CoASH released was measured by titrating the
free thiol groups with the DTNB and measuring change in absorbance at 412 nm.

5.6.2. Tartronate semialdehyde reductase assay:
Protein extracts were obtained by bead-beating cells in 50 mM KH2PO4 buffer
(pH 7.0) containing protein inhibitors mix (Sigma) then centrifuging them in a
tabletop centrifuge for 30 min at 14,000 rpm at 4˚C. TSAR assays were done
essentially as described in Hansen and Hayashi (1962). In a 1 ml cuvette at room
temperature, in 100 mM KH2PO4 buffer (pH 7.0), 0.33 mM NADH, 0.1 mM
glyoxylate, and 50 microliters of protein extract were mixed. Tartronate
semialdehyde was generated by adding 10 mM MgCl2 and 0.1 mg TPP at t = 5
minutes. Generation of d-glycerate from tartronic semialdehyde, catalyzed by
tartronate semialdehyde reduction, was measured by recording the disappeance
of NADH at 340nm.
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Appendix A.
MycoMarT7 transposon mutants on the ∆glcB∆ald (dg-tn) mutant strain
of Mycobacterium smegmatis with growth phenotypes on minimal
media plates containing glucose (G), acetate (A) or methyl-palmitate
(M) as the sole carbon sources.
Mutant
Name

Phenotype

dg-tn-1AC5

D+A-M+

fadD28

Fatty acyl-CoA ligase

dg-tn-1BD1

D~A+M+

n.a.

n.a.

dg-tn-2AH6

D~A-M-

thiO/thiE

dg-tn-4AA4

D+A-M-

icl1

Thiamine synthesis
oxidoreductases
Isocitrate Lyase 1

dg-tn-8AD4

D+A~M~

fixA

Electron transfer

Identity of
Rv
homolog

Annotated Function
in TubercuList

flavoprotein

dg-tn-8BA4

D+A~M-

Rv0338c

Fe-S binding reductase

dg-tn-9AH2

D+A-M+

acs

Acetyl-CoA synthase

dg-tn-12AA3

D+A-M-

icl1

Isocitrate lyase 1

dg-tn-13BD1

D-A+M+

dut

dUTP pyrophosphatase

dg-tn-14AA4

D+A~M~

Rv2974c

Conserved hypothetical

dg-tn-14AG2

D+A-M-

gcl

Glyoxylate carboligase

dg-tn-15BD3

D+A-M-

icl1

Isocitrate lyase 1

dg-tn-15BF2

D~A-M+

ctaB

Cytochrome c oxidase

dg-tn-17BA1

D+A-M+

acs

Acetyl-CoA synthase

dg-tn-17BB5

D+A-M-

fadD1

Fatty acyl-CoA ligase

dg-tn-17BD5

D+A-M-

icl1

Isocitrate lyase 1
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dg-tn-19AH6

D+A-M+

acs

Acetyl-CoA synthase

dg-tn-20BB5

D+A-M+

n.a.

n.a.

dg-tn-23BH1

D+A-M+

acs

Acetyl-CoA ligase

dg-tn-25AG3

D+A-M+

acs

Acetyl-CoA synthase

dg-tn-54C2

D+A-M-

sdhD

Succinate dehydrogenase D

dg-tn-56B5

D+A-M-

icl1

Isocitrate lyase 1

Approximately 4,000 mutants containing the φMycoMarT7 transposon (a kind gift
from Dr. Eric Rubin, Harvard School of Public Health) were screened for loss of
the ability to grow on glucose, acetate or methyl-palmitate as the sole carbon
source in minimal basal agar plates. Mutants with desired phenotypes were then
re-screened and the insertion site of the transposon was identified by sequencing
the region downstream of the insertion. DNA sequences were aligned against the
Mycobacterium tuberculosis genome http://genolist.pasteur.fr/TubercuList/. Two
mutants did not have clear homologs in M. tuberculosis.
All 24 mutants were transformed with an integrative copy of the M. tuberculosis
malate synthase (glcB) gene under the control of the endogenous promoter, and
the transformants were tested for complementation of the respective phenotypes
by glcB. 3 of the 24 mutants were complemented by glcB: mutant 2AH6, mutant
14AG2, and mutant 17BB5. These three mutants are underlined in the table.
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Appendix B.

Mycobacterium smegmatis φMycoMarT7 transposon

mutants with
growth phenotype on minimal media plates containing glucose (G),
acetate (A) or methyl-palmitate (M) as the sole carbon sources.
Mutant Name

Phenotype

Identity
of
Rv
homolog

mc-tn-2D8

D+A-M-

icl1

Isocitrate lyase 1

mc-tn-6C3

D+A~M+

Rv3588c

Carbonic anhydrase

mc-tn-6C7

D-A+M+

ppgK

Polyphosphate glucokinase

mc-tn-7A11

D+A-M-

Icl1

Isocitrate Lyase 1

mc-tn-11C7

D+A~M+

gltA2

Citrate synthase

mc-tn-11C11

D+A-M+

n.a.

n.a.

mc-tn-11D1

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-13E5

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-21B6

D+A-M-

icl1

Isocitrate lyase 1

mc-tn-22D8

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-24D5

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-26D2

D+A-M-

icl1

Isocitrate lyase 1

mc-tn-31F4

D+A-M+

Rv3662c

Conserved hypothetical

mc-tn-33C11

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-37B5

D+A-M-

icl1

Isocitrate lyase 1

mc-tn-38B8

D+A~M+

Rv1342c

Conserved membrane

Annotated Function
in TubercuList

protein
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mc-tn-39E7

D+A~M-

Rv0338c

Fe-S binding reductase

mc-tn-43H1

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-45C8

D~A~M~

argH

Argininosuccinate lyase

mc-tn-45F8

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-47G4

D~A~M~

nirA

Nitrite reductase

mc-tn-49E11

D+A~M-

Rv0338c

Fe-S binding reductase

mc-tn-53H5

D-A-M+

Rv2974c

Conserved hypothetical

mc-tn-54D8

D+A-M+

acs

Acetyl-CoA synthase

mc-tn-54H4

D~A~M~

nirA

Nitrite reductase

mc-tn-58B7

D+A-M-

pckA

Phosphoenolpyrivate
carboxykinase

mc-tn-60B9

D+A~M~

Rv1841c

Conserved hypothetical

mc-tn-67H8

D+A~M~

glcB

Malate synthase

mc-tn-68C6

D+A-M+

Rv2468c

Conserved hypothetical

mc-tn-69F10

D+A~M+

n.a.

n.a.

Approximately 7,000 mutants containing the fMycoMarT7 transposon (a kind gift
from Dr. Eric Rubin, Harvard School of Public Health) were screened for loss of
the ability to grow on glucose, acetate or methyl-palmitate as the sole carbon
source in minimal basal agar plates. Mutants with desired phenotypes were then
re-screened and the insertion site of the transposon was identified by sequencing
the region downstream of the insertion. DNA sequences were aligned against the
Mycobacterium tuberculosis genome at http://genolist.pasteur.fr/TubercuList/.
All but two of the mutants had clear homologs in M. tuberculosis. Mutant 11C11
has some homology to D-amino-acylases from various bacterial species; mutant
69F10 has homology to “probable transporter proteins”. The work to study these
mutants, along with the entire 7,000+ library that was generated in this genetic
screen, was done by Michael Silverman and Lubomir Merkov.
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